

George N. Dalekos, MD, PhD

PROFESSOR OF MEDICINE

HEAD OF THE DEPARTMENT OF

MEDICINE AND THE RESEARCH

LABORATORY OF INTERNAL MEDICINE

**NATIONAL EXPERTISE CENTER IN AUTOIMMUNE LIVER
DISEASES, GENERAL UNIVERSITY HOSPITAL OF LARISSA**

LARISSA, GREECE

<http://www.med.uth.gr/internalmedicine/>

**CURRICULUM VITAE
(Brief Edition)**

LARISSA, December 2020

Curriculum Vitae

First name: George
Family's name: Dalekos
Father's name: Nikolaos
Mother's name: Eymorphia
Place of birth: Athens, Greece
Date of birth: November 23, 1960
Citizenship: Greek
Profession: Professor of Medicine, Head, Department of Medicine and the Research Laboratory of Internal Medicine, University of Thessaly, Medical School.
Marital Status: Married, father of two children
Home address: M. Dorotheou 1b, 41447 Larissa, Greece
Office address: University of Thessaly, Faculty of Health Sciences, Medical School, Biopolis, 41110 Larissa, Greece
Telephone: 0030-241350-2285 (secretary)/ 0030-2410-685726
Fax: 0030-241350-1557
e-mail georgedalekos@gmail.com; dalekos@med.uth.gr
Languages: Greek, English

Education

1985 MD, Athens Medical School, University of Athens, Greece
 1995 Doctoral Thesis, Ioannina Medical School, University of Ioannina, Greece

Professional Experience

Oct 1985 - Nov 1987: Obligatory service in the Greek Army
 Nov 1986 - Nov 1987: House officer, Athens Navy Hospital (during my military service) (Director: Assistant Professor A. Perperas).
 Nov 1987 - May 1988: Research Fellow, Unit of Gastrointestinal Endoscopy, Athens Navy Hospital (Director: Assistant Professor N. Nikolopoulos).
 May 1988 - June 1989: Senior House officer, Division of Internal Medicine, Psychiatric Hospital of Attica (Director: Dr. A. Perrakis).
 July 1989 - Dec 1990: Obligatory medical service in rural area (Health Center of Andros Island).
 January 1991 - May 1992: Honorary Research Fellow, Laboratory of Clinical Immunology, Department of Internal Medicine, Ioannina Medical School, University of Ioannina (Director: Professor H.M. Moutsopoulos).

- May 1992 - May 1995: Chief Resident, Division of Internal Medicine, Ioannina Medical School, University of Ioannina (Directors: Professor H.M. Moutsopoulos until Nov 1993 and then Professor D. Sideris) and Research Associate, Laboratory of Clinical Immunology, Department of Internal Medicine, Ioannina Medical School, University of Ioannina (Director: Professor H.M. Moutsopoulos).
- June 1995 – April 1996: Research Associate, Department of Internal Medicine, (Hepato-Gastroenterology Division) Ioannina Medical School, University of Ioannina (Director: Professor E.V. Tsianos).
- May 1996 - Feb 1997: Senior Registrar in Internal Medicine, Blood Bank at the University Hospital of Ioannina. (Director: Dr. E. Zervou) and Research Associate, Department of Internal Medicine, (Hepato-Gastroenterology Division) Ioannina Medical School, University of Ioannina (Director: Professor E.V. Tsianos).
- March 1997 – Oct 1997: Senior Registrar in Internal Medicine, Division of Internal Medicine, Ioannina Medical School, University of Ioannina (Director: Professor E.V. Tsianos) and Research Associate, Department of Internal Medicine, (Hepato-Gastroenterology Division) Ioannina Medical School, University of Ioannina (Director: Professor E.V. Tsianos).
- Oct 1997 – Oct 1998: Post Doc Research Fellow in the Department of Gastroenterology and Hepatology, Hannover Medical School (Director: Professor M.P.Manns).
- Nov 1998 – Dec 2002: Assistant Professor of Medicine, University of Thessaly, Faculty of Health Sciences, Medical School*.
- Jan 2003 – August 2008: Associate Professor of Medicine, University of Thessaly, Faculty of Health Sciences, Medical School*.
*Chief of the Academic Liver Unit and 2nd Word of Internal Medicine Clinic, University Hospital of Larissa, Greece and Associate Director in the Research Lab of Internal Medicine, University of Thessaly, Medical School, Larissa, Greece since November 1998.
- June 2007 – June 2011: Head of the Research Group of Investigational Medicine, Institute of Biomedical Research & Technology, CERETETH, Larissa, Greece
- August 2008 – now: Professor of Medicine, Head of the Department of Medicine, the Academic Liver Unit and the Research Lab of Internal Medicine, University of Thessaly, Medical School, Larissa, Greece.

Licence to Practice Medicine and Speciality Certification

- 1985 Certificate of Registration, as a Medical Practitioner (Ministry of Health, Athens, Greece).
- 1995 Certificate of Internal Medicine

Member of Societies

- 1990 Society for Medical Studies (Greek)
- 1994 Hellenic Association for the Study of the Liver (Greek)
- 1996 Hellenic Society of Internal Medicine (Greek)
- 1996 The New York Academy of Sciences
- 1996 European Society for Free Radical Research
- 1997 European Association of Gastroenterology and Endoscopy
- 1997 Hellenic Association of Immunology (Greek)
- 1997 European Federation of Internal Medicine

1999	European Association for the Study of the Liver
2001	Hellenic Society of Systemic Autoimmune Diseases (Greek)
2001	California Blood Bank Society
2008	International Association for the Study of Liver Diseases (IASL)
2008	Hellenic Society of Internal Medicine of Northern Greece (Greek)
2013	American Association for the Study of Liver Diseases (AASLD)

Awards

1. **Second award of new scientist** by the **Hellenic Hypertension Society** for the study entitled: «*Interleukin-1 β in the systemic circulation of patients with familial hypercholesterolaemia and essential hypertension: additional risk factor for atheromatosis in hypertensive patients?*» presented in the **5th Panhellenic Congress in Hypertension** (February 29-March 2, 1996) as well as in the **16th Scientific Meeting of the International Society of Hypertension** (Glasgow, UK, June 23-27, 1996).
2. **1st Award of the Best Study** by the **Hellenic Society of Gastroenterology** for the study entitled: «*High concentrations of interleukin-6 (IL-6) and soluble interleukin-2 receptors (sIL-2Rs) in active ulcerative colitis after the development of a sensitive bioassay (IL-6 dependent mouse hybridoma clone B9)*» presented in the **10th World Congress of Gastroenterology**, Los Angeles, October 2-7, 1994 (preliminary), as well as in the **16th Panhellenic Congress of Gastroenterology**, Athens, October 12-16, 1996 (full version).
3. **First award** by the **Balkan Clinical Laboratory Federation** for the study entitled: «*Acute renal failure due to copper-induced rhabdomyolysis: Localisation of the injury by ¹H-NMR spectroscopy*» presented in the **5th Meeting of Balkan Clinical Laboratory Federation**, Ioannina, October 9-12, 1997.
4. **Second award** in the **8th Hellenic Symposium on Hepatitis C** for the study entitled: «*Anticardiolipin antibodies (a-CLAbs) are not b2-GPI-dependent (non-thrombogenic a-CLAbs): preliminary results in 107 HCV patients from central Greece*» presented in Athens, January 27, 2001.
5. **First award of Poster Session** by the **Hellenic Association for the Study of the Liver** for the study entitled: «*Hemopoietic progenitor cells and bone marrow stromal cells in patients with autoimmune hepatitis type 1 and primary biliary cirrhosis*» presented in the **8th Panhellenic Congress of Hepatology**, Thessaloniki, May 8-11, 2003.
6. **1st Award (Symboulidio award)** by the **Medical Association of Athens** for the **Best Research and Practice** in “*Autoimmune hepatitis and virus induced phenomena*”, Athens, May 2004.
7. **Best Oral Presentation Award** by the **European Society of Hypertension** for the study entitled: «*Effect of hydroxychloroquine treatment on atherosclerosis in ApoE deficient mice*» presented in the **21st European Meeting on Hypertension & Cardiovascular Prevention**, June 17-21, 2011, Milan, Italy.
8. **1st Award for the Best Oral Presentation** in the **10th Congress of the European Federation of Internal Medicine** for the study entitled: «*Mycophenolate for the treatment of autoimmune hepatitis: Prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of patients*» presented in Athens, 5-8 October, 2011.
9. **Second Award of Oral Presentation** in the **13th Panhellenic Congress of the Hellenic Association for the Study of the Liver** for the study entitled: “*Decreased production of hepcidin in patients with autoimmune liver diseases*” presented in Rhodes Island, May 9-12, 2013.

10. **Award of the Amphiarion Institution for Chemotherapeutic Studies by The Athens Medical Society** for the study entitled: "*Panhellenic study of resistance of Staphylococcus aureus: 2012*" presented in the **39th Annual Panhellenic Medical Congress**, Athens, May 22-25, 2013.
11. **1st Award for the Best Poster Presentation** in the **11th Panhellenic Congress of Clinical Chemistry** for the study entitled: "*Non interventional investigation of liver diseases by using caffeine test detection in urine*" presented in Volos, October 11-12, 2013.
12. **First award for the scientific work** entitled: "*Expression of HIF-1 α in atherosclerotic plaques of ApoE knock-out mice under treatment with hydroxychloroquine*" presented in the **20th Congress of Greek Medical Students**, Thessaloniki, May 9-11, 2014.
13. **1st Award of Oral Presentation** in the **1st Panhellenic Congress of Continuing Education in Internal Medicine** for the study entitled: "*Long-term outcome of patients with autoimmune hepatitis (AIH) receiving Mycophenolate Mofetil (MMF) as first line treatment*" presented in Thessaloniki, February 26-28, 2015.
14. **3rd Award of Best Oral Presentation** in the **14th Panhellenic Congress of the Hellenic Association for the Study of the Liver** for the study entitled: "*Decrease serum DNase-1 activity in patients with autoimmune liver diseases*" presented in Kos Island, May 7-10, 2015.
15. **2nd Award of Best Poster Presentation** in the **14th Panhellenic Congress of the Hellenic Association for the Study of the Liver** for the study entitled: "*Treatment of portal thrombosis in cirrhotic patients*" presented in Kos Island, May 7-10, 2015.
16. **1st Award of Best Poster Presentation** in the **14th Panhellenic Congress of the Hellenic Association for the Study of the Liver** for the study entitled: "*The role of mitogen-activated protein kinase p38 (p38MAPK) pathway on the natural history of chronic HBV infection*" presented in Kos Island, May 7-10, 2015.
17. **The work entitled:** "*Prompt initiation of intravenous corticosteroids prevents deterioration of acute/severe autoimmune hepatitis (AS-AIH) and the need for liver transplantation (LT)*" was selected for **presentation** in a **poster tour (Chair: P. Invernizzi)** during the **International Liver Congress™ 2017, 52th Annual Meeting of the European Association for the Study of the Liver**, Amsterdam, The Netherlands, April 19-23, 2017.
18. **2nd Award of Best Case Report (Oral Presentation)** in the **Educational Two-Day Conference of the Department of Northern Greece "Macedonia" of the Hellenic Society of Gastroenterology** entitled: "*Reversion of decompensated cirrhosis in a patient with autoimmune overlap syndrome*" presented in Thessaloniki, May 12 & 13, 2017.
19. **1st Award of Best Oral Presentation in the 15th Panhellenic Congress of the Hellenic Association for the Study of Liver** for the study entitled: "*Importance of IP10 in patients with HBeAg-negative chronic hepatitis B who interrupt long-term therapy with entecavir or tenofovir: Prospective study DARING-B*" presented in Larissa, May 25-27, 2017.
20. **1st Award of Best Oral Presentation** in the **37th Panhellenic Congress of the Hellenic Society of Gastroenterology** for the study entitled: "*DAA in the modern clinical practice for the treatment of chronic hepatitis C. HERACLIS: A Greek multicenter prospective clinical study*" presented in Thessaloniki, October 5-7, 2017.
21. **The work entitled:** "*Time trends in major hepatic complications in primary biliary cholangitis: incidence and transplant-free survival*" received the **AASLD Foundation Abstract Award Recipient** during **The Liver Meeting, 68th Annual Meeting of the American Association for the Study of Liver Diseases**, Washington, USA, October 20-24, 2017.
22. **The work entitled:** "*Time-dependent factors associated with diminished transplant-free survival in patients with primary biliary cholangitis and an optimal response to*

ursodeoxycholic acid after one year of treatment» received the **AASLD Presidential Poster of Distinction** during **The Liver Meeting, 68th Annual Meeting of the American Association for the Study of Liver Diseases**, Washington, USA, October 20-24, 2017.

23. **1st Award of Best Oral Presentation** in the **16th Panhellenic Congress of the Hellenic Association for the Study of the Liver** for the study entitled: “*Metabonomic profile of patients with autoimmune hepatitis at diagnosis and during remission by ¹H NMR spectroscopy*” presented in Athens, May 4-6, 2018.
24. **The work entitled:** «*Impact of geographical region on death or transplantation and on malignancy in primary sclerosing cholangitis - a multicenter retrospective study of the international PSC study group (IPSCSG)*» received the **AASLD Presidential Poster of Distinction** during **The Liver Meeting, 69th Annual Meeting of the American Association for the Study of Liver Diseases**, San Francisco, USA, November 9-13, 2018.
25. **3rd Award of Best Oral Presentation** in the **17th Panhellenic Congress of the Hellenic Association for the Study of the Liver** for the study entitled: “*Significance of serum HBsAg levels on the prognosis of non-cirrhotic patients with chronic HBeAg negative hepatitis B who discontinue long-term antiviral therapy*” presented in Kalamata, May 9-11, 2019.
26. **The work entitled:** «*Altered expression of DNA methylation/hydroxymethylation enzymes in patients with autoimmune hepatitis*» received the **FDIME (Federation for the Development of Internal Medicine in Europe) Research Grant Award** during the **18th European Congress of Internal Medicine of the European Federation of Internal Medicine**, Lisbon, Portugal, August 29-31, 2019.
27. **The work entitled:** «*The diverse face of familial Mediterranean fever (FMF) in Greece: The importance of R202Q mutation of Mediterranean fever (MEFV) gene*» received the **FDIME (Federation for the Development of Internal Medicine in Europe) Best Research Abstract Award** during the **18th European Congress of Internal Medicine of the European Federation of Internal Medicine**, Lisbon, Portugal, August 29-31, 2019.
28. **1st Award of Best Oral Presentation** in the **18th Panhellenic Congress of the Hellenic Association for the Study of the Liver** for the study entitled: “*Epigenetic alterations in autoimmune hepatitis (AIH)*”, Athens, September 11-13, 2020.
29. **1st Award of Basic research** in the **9th National Congress of the Hellenic Atherosclerosis Society** for the study entitled: “*Crocin exerts antiatherogenic effects in apolipoprotein E knockout mice via modulation of endothelial nitric oxide synthase and hypoxia-inducible factor 1 alpha*”, Ioannina, December 3-5, 2020.

Other activities

1. **Official Member of the International Autoimmune Hepatitis Group** (IAIHG, Decision of the Executive Committee since 2002-now).
2. **Member of the Provisional Steering Committee** of the **IAIHG** (Paris, April 2018).
3. **Regular and adhoc Reviewer for Research Projects in Gastroenterology and Hepatology** on behalf of *Wellcome Trust (England)*.
4. **Regular and adhoc Reviewer for Research Projects** on behalf of the *Medical Research Council, UK*.
5. **Regular and adhoc Reviewer for Research Projects** on behalf of the *Austrian Science Fund, Austria*.
6. **Member of the International PSC Study Group** (2012-now).
7. **Official peer reviewer for research projects of the University of Bologna** (2013-now).

8. **Member of the Hepatitis Delta International Network.**
9. **Principal and/or secondary Supervisor of 35 PhD students (2000-2018) who have completed efficiently their thesis (in most cases on issues on liver autoimmunity or chronic viral hepatitis B and C).**
10. **Regular or Adhoc Reviewer for 163 journals:** Acta Parasitologica, Advances in Clinical Chemistry, Advances in Medical Sciences, African Journal of Parasitology Research, Age & Ageing, Aging Clinical and Experimental Research, Alimentary Pharmacology & Therapeutics, Annals of Gastroenterology and Digestive Disorders, Annals of Hepatology, Annals of Internal Medicine, Annals of Translational Medicine, Applied Physiology Nutrition and Metabolism, Archives of Organ Transplantation, Archivum Immunologiae et Therapiae Experimentalis, Arthritis Research & Therapy, Autoimmunity, Autoimmunity Highlights, Autopsy and Case Reports, BioMed Research International, Biomedical and Environmental Sciences, British Journal of Medicine and Medical Research, BMC Gastroenterology, BMC Public Health, BMJ Case Reports, BMJ Open Gastroenterology, Book entitled "Framing the Knowledge of Viral Hepatitis" (Editor Dr. Raymond Schinazi), Canadian Journal of Gastroenterology and Hepatology, Canadian Journal of Physiology and Pharmacology, Cancer Investigation, Cancer Management and Research, Case Reports in Infectious Diseases, Case Reports in Orthopedics, Cells, Cell and Tissue Research, Central European Journal of Immunology, Clinica Chemica Acta, Clinical Chemistry and Laboratory Medicine, Clinical and Experimental Immunology, Clinical and Experimental Medicine, Clinical Immunology, Clinical Infectious Diseases, Clinical Neurology and Neurosurgery, Current Clinical Pharmacology, Current Pharmaceutical Design, Digestive Diseases and Sciences, Digestive and Liver Disease, Disease Markers, Epigenomics, European Journal of Clinical Investigation, European Journal of Clinical Microbiology & Infectious Diseases, European Journal of Internal Medicine, European Journal of Therapeutics, European Medical Journal, Expert Opinion on Drug Metabolism and Toxicology, Expert Opinion on Pharmacotherapy, Expert Review of Anti-infective Therapy, Expert Review of Clinical Immunology, Expert Review of Gastroenterology and Hepatology, Expert Review of Molecular Diagnostics, Folia Medica, Future Microbiology, Future Virology, Gastroenterology, GERMS (Official Journal of the European HIV/AIDS and Infectious Diseases Academy), Gut, Hellenic Journal of Gastroenterology (τόρα Annals of Gastroenterology), Hellenic Journal of Medicine, Hemodialysis International, Hepatic Medicine: Evidence and Research, Hepatitis Monthly, Hepatology, Hepatology International, Human Immunology, Immunological Investigations, Immunology Letters, Immunometabolism, Immunotherapy, Infection and Drug Resistance, Infection Genetics and Evolution, International Journal of Applied Microbiology and Biotechnology Research, International Journal of Artificial Organs, International Journal of Biochemical Research & Review, International Journal of Hepatology and Gastroenterology, International Journal of Immunopathology and Pharmacology, International Journal of Infectious Diseases, International Journal of Medical Sciences, International Journal of Respiratory and Pulmonary Medicine, International Journal of Tropical Disease & Health, International Research Journal of Biochemistry and Biotechnology, International Urology and Nephrology, Iranian Red Crescent Medical Journal, Journal of Autoimmune Diseases, Journal of Autoimmune Diseases and Rheumatology, Journal of Bacteriology and Parasitology, Journal of Bioenergetics and Biomembranes, Journal of Blood Disorder and Medicine, Journal of Cancer Research and Therapeutics, Journal of Cancer and Tumor International, Journal of Clinical Gastroenterology, Journal of Clinical Investigation, Journal of Clinical Laboratory Analysis, Journal of Clinical and Laboratory Medicine, Journal of Clinical Pathology, Journal of Clinical Pharmacy and Therapeutics, Journal of Clinical and Translational Hepatology, Journal of Digestive Diseases and Hepatology, Journal of Gastroenterology and Hepatology, Journal of Gastrointestinal and Liver Diseases, Journal of Hepatitis, Journal of Hepatocellular Carcinoma, Journal of Hepatology, Journal of Hepatology

Reports, Journal of Immunological Methods, Journal of Infection, Journal of Laboratory and Clinical Medicine, Journal of Laboratory Medicine, Journal of Medical Virology, Journal of Microbiology, Immunology and Infection, Journal of Microbiology and Infectious Diseases, Journal of Postgraduate Medicine, Journal of Rheumatology, Journal of Translational Internal Medicine, Journal of Veterinary Science, Journal of Viral Hepatitis, Journal of Virology and Microbiology, Journal of Zhejiang University-SCIENCE B, Lancet Infectious Diseases, Liver International, Medical & Biological Engineering & Computing, Medical Science Monitor, Mediterranean Journal of Hematology and Infectious Diseases, Memórias do Instituto Oswaldo Cruz, Merit Research Journal of Medicine and Medical Sciences, Metabolism, Microbes and Infection, MicroRNA, Mini – Reviews in Medicinal Chemistry, Molecular and Cellular Endocrinology, Molecules, OBM Transplantation, Open Access Surgery, Open Rheumatology Journal, Ophthalmology, Pathogens and Global Health, PEDIATRICS, QJM, Redox Report, Reviews in Medical Virology, Scandinavian Journal of Gastroenterology, Scientific Reports, SciFed Biotech and Bioengineering Journal, Stem Cells International, Therapeutic Advances in Gastroenterology, Therapeutic Advances in Infectious Diseases, Therapeutics and Clinical Risk Management, Tissue and Cell, Turkish Journal of Gastroenterology, United European Gastroenterology Journal, Viruses, World Journal of Cardiology, World Journal of Clinical Cases, World Journal of Gastroenterology, World Journal of Hepatology.

11. **Reviewer of abstracts** on behalf of the **International Liver Congress (EASL Annual meetings)**, years 2012, 2013 and 2014).
12. **Member of the Global PBC International Study Group** (2014-now).
13. **Assistant Editor and Section Editor** in Immunology for *the Hellenic Journal of Gastroenterology* (1997 – 1999; now *Annals of Gastroenterology*).
14. **Member of the Editorial Board and Section Editor** for Autoimmune Liver Diseases and Virus Induced Autoimmunity in the *Journal of Autoimmune Diseases* (2004-2009).
15. **Member of the Editorial Board** of *Journal of Hepatology* (2007-2009 and 2010-2014).
16. **Member of the Editorial Board** of *Liver International* (2008-2012).
17. **Member of the Editorial Board** of *World Journal of Gastroenterology* (2007-2009 and 2014-2017).
18. **Member of the Editorial Board** of *Autoimmune Diseases* (2009-2014).
19. **Member of the Editorial Board** of *World Journal of Gastrointestinal Pathophysiology* (2011-2015).
20. **Member of the Editorial Board** of *World Journal of Hepatology* (2013-2017).
21. **Member of the Editorial Board** of *Journal of Translational Internal Medicine* (2014-now).
22. **Member of the Editorial Board** of *Hellenic Journal of Medicine (Official Journal of the Internal Medicine Society of Greece)* (2013-2018).
23. **Academic Editor** of *Case Reports in Infectious Diseases* (2018-now)
24. **Member of the Editorial Board** of *Journal of Autoimmune Diseases and Rheumatology* (2018-now).
25. **Member of the Editorial Board** of *Immunity (Official Journal of the Hellenic Society of Immunology)* (2018-now).
26. **Member of the Editorial Board** of *Cancers* (2019-now).
27. **Participant investigator** of the European Collaborative Study on the Incidence of Inflammatory Bowel Disease (10. 1991 - 9. 1993) published in *Gut, European Journal of*

Gastroenterology and Hepatology and Inflammatory Bowel Disease in 1996, 1997 and 1998 respectively (see International Publications No: 22, 25, 27).

28. **Participant principal investigator** in a local (Greek) randomised controlled trial for the treatment of naïve HCV patients with pegylated interferon-a2b plus ribavirin published in *J Gastrointest Liver Dis* (see International Publications No: 79).
29. **Participant principal investigator** in the collaborative study with Professor J-M Pawlotsky, University of Paris, France regarding the Clinical Significance of hepatitis B virus DNA levels in HBeAg-negative, HBV-genotype D-infected patients published in *Hepatology* 2004; 40(Suppl.1):675A, *Journal of Clinical Virology* 2006; 36 (Suppl.): S78, *Journal of Hepatology* 2005; 42 (Suppl.): 489.
30. **Collaboration** with Professor D. Vergani (King's College London) and Professor J. Rodes (Barcelona, Spain) on the prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis published in *Gut* (see International Publications No: 61), on the clinical significance of isotype specific antimitochondrial antibodies in primary biliary cirrhosis published in *Liver International* (see International Publications No: 100) on the clinical significance of anti-gp210 antibodies published in *Hepatology* (see International Publications No: 97) and on the significance and correlation of AMA detected by indirect immunofluorescence and immunoblot published in *Liver International* (see International Publications No: 95).
31. Sponsor and **principal investigator** along with Professor M.P. Manns (Hannover, Germany) and Professor C. Yurdaydin (Ankara, Turkey) on Investigator Protocol entitled: "A multicenter randomized study comparing the efficacy of adefovir dipivoxil vs. pegylated interferon-alfa-2a plus placebo vs. adefovir dipivoxil plus pegylated interferon-alfa-2a for the treatment of chronic delta hepatitis" (2004-2006), published in *Liver International*, *New England Journal of Medicine*, *Antiviral Therapy*, *Journal of Viral Hepatitis*, *Turkish Journal of Gastroenterology and Hepatology* (see International Publications No: 124,133,141,145,150,169,170).
32. **Collaboration** with Prof. M.P. Manns (Hannover, Germany) and Prof. H. Tillmann (Leipzig, Germany) on the safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience, which is published in *Journal of Viral Hepatitis* (see International Publications No: 74).
33. **Participant principal investigator** in the "Phase 3b, Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients with Lamivudine-Resistant Chronic Hepatitis B Who Have Limited Treatment Options (GS-01-550)", which has been completed in March 2004.
34. **Participant principal investigator** in a multicenter, double blinded study in patients with chronic hepatitis C who are non-responders to prior peginterferon-a or peginterferon-a + ribavirin therapy comparing treatment with thymosin a1 + peginterferon-a-2a plus ribavirin with peginterferon-a-2a + ribavirin + placebo (2005-2008, Co-ordinator: Professor M. Rizzetto).
35. **Participant principal investigator** in a multicenter, double blinded study on Tenofovir vs Adefovir in the treatment of naïve patients with chronic anti-HBe positive hepatitis B (2006-2016; we have been audited for this study by American authorities funded by Gilead with excellent conclusions).
36. **Participant principal investigator** in a multicenter, Phase 3b, randomized, double-blind, double-dummy study, evaluating the antiviral efficacy, safety, and tolerability of Tenofovir Disoproxil Fumarate monotherapy versus Emtricitabine plus Tenofovir DF fixed-dose combination therapy in subjects with chronic hepatitis B who are resistant to lamivudine (2009-2010).

37. **Participant principal investigator** in a multicenter, non-interventional Phase IV study entitled: “Prognostic factors of long term response to treatment with pegylated interferon alpha-2a in HBeAg negative chronic hepatitis B patients” (2009-2012, Roche, PERSEAS) (see International Publications No. 179).
38. **Collaboration** with Prof. M.P. Manns (Hannover, Germany) and Prof. H. Wedemeyer (Hannover, Germany) on the cross-genotype reactivity of the immunodominant HCV-CD8 T-cell epitope NS3-1073 which is published in *Vaccine* (see International Publications No: 112).
39. **Partner (member)** of the E-RARE “Epinostics” Consortium of Europe (2007-10) entitled: “Autoimmune liver diseases: Epitope peptide mapping – The entry to novel and innovative diagnostic and therapeutic applications” funded by European Union (740,000 €).
40. **Participant principal investigator** in a multicentre study of the International Autoimmune Hepatitis Group regarding the development of the simplified criteria for the diagnosis of autoimmune hepatitis published in *Hepatology* (see International Publications No: 103).
41. **Participant principal investigator** in a multicentre study regarding the prompt, rapid and safe detection of IgG and IgA antimitochondrial and ANA-PBC specific antibodies which is published in *Journal of Autoimmunity* (see International Publications No: 130).
42. **Participant principal investigator** in a study with industry (Boca Biolistics, USA) entitled «Hepatitis B, Hepatitis C and HIV sample collection study» (BB-ID-034, 2010-2014).
43. **Participant principal investigator** in a study entitled: “Multicenter, Open-Label, study of Telaprevir in Combination with Peginterferon Alfa and Ribavirin in Genotype 1 Chronic Hepatitis C Subjects with Severe Fibrosis and Compensated Cirrhosis” (VX-950HEP3002, 2011-2014).
44. **Participant principal investigator** in a study entitled: “A phase III, randomized, double-blind trial to evaluate the efficacy, safety and tolerability of TMC435 vs telaprevir, both in combination with Peg-IFN α -2a and ribavirin, in chronic hepatitis C genotype-1 infected subjects who were null or partial responders to prior Peg-IFN α and ribavirin therapy” (TMC435HPC3001, 2012-2013).
45. **Participant principal investigator** in a study entitled: “Non-Interventional Cohort Study on the Utilization and Impact of Dual and Triple Therapies Based on Pegylated Interferon for the Treatment of Chronic Hepatitis C” (MV25599, 2012-2017).
46. **Participant principal investigator** in a study entitled: “An international, Multi-Center Study Evaluating the Correlation of IL28B Genotypes with Chronic Hepatitis C Disease Characteristics and Patient Demographics” (MV25600, 2012-2014).
47. **Participant principal investigator** in a multicentre study regarding the detection of new gene loci for primary sclerosing cholangitis (PSC Genetics Study – IMMUNOCHIP Project) which is published in *Nature Genetics* (see International Publications No: 159).
48. **Participant principal investigator** in a study entitled: “EU-CORE: European Registry of Outcome and Experience from CUBICIN use for the treatment of severe infections from Gram positive bacteria” (CCBC134A2403, 2011-2012).
49. **Participant principal investigator** in a study entitled: “A double-blind, randomized, placebo-controlled, multicenter study assessing the impact of additional LDL-Cholesterol reduction on major cardiovascular events when AMG 145 is used in combination with statin therapy in patients with clinically evident cardiovascular disease” (2013-2017).
50. **Participant principal investigator** in a study entitled: “Use of boceprevir in addition to standard Pegylated Interferon alpha and Ribavirin regimen in genotype 1 Chronic Hepatitis C treatment-experienced patients in the Greek routine clinical practice” (2013 – 2015).

51. **Participant principal investigator** in a study entitled: “OPTIMIS - Outcomes of HCC patients treated with TACE followed or not followed by sorafenib and the influence of timing to initiate sorafenib” (BAY 43-9006, Sorafenib / study identifier: 16560/NX 1301) (2013 – 2016).
52. **Collaboration** with Prof. G.V. Papatheodoridis, Prof. P. Lampertico and Prof. M. Buti on the development of a prognostic score (PAGE-B) for the detection of HCC in chronic anti-HBe positive chronic HBV patients under treatment with entecavir or tenofovir which is published in *J Hepatol* (see International Publications No: 174 and 190).
53. **Participant principal investigator** in a study entitled: “A phase IV, blood sample collection study for exploratory evaluation of the association of single nucleotide polymorphisms with treatment responses from subjects with HBe-Ag positive or negative chronic hepatitis B, who received therapy for hepatitis B with peginterferon alpha-2a 40kD±Nucleos(t)ide analogue” (Sponsor: F-Hoffmann-LaRoche Ltd) (2014-2015).
54. **Participant principal investigator** in a study entitled: “An international multicenter prospective observational study to evaluate epidemiological, humanitarian and economic outcomes of treatment for chronic hepatitis C” (2014 - 2015) (ABBVIE).
55. **Participant principal investigator** in a phase IIIb/IV randomized, controlled, open label, parallel group study entitled: “Comparison of the efficacy of vancomycin therapy to extended duration fidaxomicin therapy in the sustained clinical cure of *Clostridium difficile* infection in an older population” (EXTENDED Study, 2014-2016).
56. **Principal investigator** in a study entitled: “The role of gene polymorphism of PD-1.3 in the natural history and response to treatment of chronic hepatitis B and C” (Gilead: 2014 – 2017).
57. **Participant principal investigator** in a randomized, multicenter, phase 2 study to evaluate safety and efficacy of subcutaneous injections of RG-101 in combination with oral agents in treatment naïve, genotype 1 and 4 chronic hepatitis C patients (RG101-02) (2016 – 2018).
58. **Principal investigator and Co-ordinator** in a funding project by the Hellenic Association for the Study of the Liver (HASL) entitled: «Metabonomic profile of patients with autoimmune liver diseases by NMR spectroscopy: Clinical significance on the diagnosis, outcome and prognosis» (6/2015-6/2017).
59. **Participant principal investigator and Co-ordinator** in a study entitled: “Prognostic factors of sustained virological and biochemical response and immunological changes in patients with chronic HBeAg-negative hepatitis B in whom the long-term effective treatment with antivirals has been discontinued” (Sponsor: Gilead) (2015 – 2017).
60. **Participant principal investigator and Co-ordinator** in a national retrospective/prospective study of the Greek autoimmune hepatitis registry (Hellenic Association for the Study of the Liver, 2016 – now).
61. **Principal investigator** of an Open randomized clinical study entitled: “Assesment of safety and efficacy of mycophenolate mofetil vs azathioprine in the induction of remission and sustained response after complete treatment withdrawal in treatment naïve patients with autoimmune hepatitis” (2016 – now).
62. **Participant principal investigator** in a multi-center, parallel group, open-label, phase 2 study to evaluate the efficacy and safety of a single subcutaneous injection of RG-101 compined with Oral GSK2878175 taken once daily for 6, 9, or 12 weeks in treatment naïve, genotype 1 and 3, chronic hepatitis C patients (RG101-04) (2016 – now).
63. **Principal investigator/co-ordinator** in a retrospective study entitled: “Moving from biochemically early to advanced PBC: Are there any prognostic factors?” (Global PBC Study Group) (2016 – 2019).

64. **Participant principal investigator** in an observational, long-term safety and efficacy follow-up study of subjects who have previously received RG-101 (RG101-05) (2016 – 2017).
65. **Participant principal investigator** in a retrospective study for the assessment of biomarkers for liver inflammation and their impact on the prognosis of PSC – Particularly, the impact of serum IgG and ALT levels on disease progression will be analysed, then the impact of immunosuppressive treatment (International PSC Study Group, 2016 – now).
66. **Participant principal investigator and Co-ordinator** in a study entitled: “Diagnostic performance of FibroMeter (ECHOSENS) in the assessment of liver fibrosis alone or in combination with Fibroscan (ECHOSENS) (2016 – 2018).
67. **Participant principal investigator** in a phase II multicentre study entitled: “Efficacy and safety of subcutaneously administered semaglutide in patients with NASH” (NN9931-4296) (2016 – 2020).
68. **Participant principal investigator and Co-ordinator** in a multicentre study entitled: “AIH and NAFLD/NASH: i) Do all NASH patients have truly only NASH? ii) NAFLD/NASH in AIH: important player or innocent bystander?” of the International AIH Group (2016-now).
69. **Participant principal investigator and Co-ordinator** in a multicentre study entitled: “Prevalence and significance of antimitochondrial antibodies in patients with autoimmune hepatitis” of the International AIH Group (2016-now).
70. **Participant principal investigator** in the EURICA phase III study entitled: “Prospective observational study of risk factors, clinical management and outcomes of hospitalized patients with serious infections caused by carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii (2017-2018).
71. **Participant principal investigator** in a Greek prospective multicenter study entitled: “Natural history of portal vein thrombosis in patients with decompensated cirrhosis” (2017 – 2020).
72. **Participant principal investigator** in a phase IIA study entitled: “Phase IIA exploratory study of oral milciclib maleate in patients with unresectable or metastatic hepatocellular carcinoma” (CDKO-125a-010) (2017 - 2019).
73. **Participant** in a multicenter prospective study entitled: “A European, observational, three-year cohort comparative study on the safety of the fixed-dose combination pravastatin 40mg/fenofibrate 160 mg (Pravafenix®) versus statin alone in real clinical practice”. (POSE: Pravafenix® Observational Study in Europe) (2017-now).
74. **Participant principal investigator** in a phase IIIb study entitled: “A single arm, open-label study to evaluate the efficacy and safety of Glecaprevir (GLE) / Pibrentasvir (PIB) in treatment naïve adults with chronic hepatitis C virus (HCV) genotype 1, 2, 4, 5, or 6 infection and compensated cirrhosis (M16-135 - ABBVIE)” (2017-2019).
75. **Participant principal investigator** in a phase II study entitled: “A double blind, randomized, controlled with placebo clinical study, for the assessment of efficacy and safety of GKT 137831, in patients with primary biliary cholangitis under ursodeoxycholic treatment and persistently elevated alkaline phosphatase” (2017-2019).
76. **Participant principal investigator** in an observational study entitled: “EU-Wide Cross-sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care” (DA VINCI 20150333, 2018 - 2019).
77. **Participant principal investigator** in an observational study by the IAIHG entitled: “Long-term outcome and risk stratification in autoimmune hepatitis – an international, multicenter retrospective observational study” (2018-now).
78. **Collaboration** with Prof. Y. Renaudineau Brest University, France in the project entitled: “Epigenetics in autoimmune liver diseases” (2018-2020).

79. **Participant** in the Γ.Γ.E.T- ΕΠAvEK project entitled: “Novel technologies for surveillance and characterization of Extended-spectrum β -lactamase and Carbapenemase producing Enterobacteriaceae, in humans and animals” (2018 – now).
80. **Participant principal investigator** in a retrospective study entitled: “Screening and management of dominant strictures in PSC: A multicenter cohort analysis (International PSC Study Group, 2018 – now).
81. **Participant principal investigator** in a retrospective study entitled: “Surveillance strategies for hepatobiliary malignancy” (International PSC Study Group, 2018 – 2020).
82. **Participant principal investigator** in a phase IIb study entitled: “A prospective, randomized, open-label, comparative study to assess the efficacy, safety and tolerability of aztreonam-avibactam (ATM-AVI) and best available therapy for the treatment of serious infections due to multi-drug resistant Gram-negative bacteria producing metallo-B-lactamase (MBL) (Pfizer 2019 – now).
83. **Collaboration** with Prof. Simos, Faculty of Health Science and the Hellenic Pasteur Institute in the project entitled: “Hepcidin, the central regulator of iron homeostasis, as diagnostic biomarker and personalized therapeutic agent”. (2019 – now).
84. **Principal investigator and Co-ordinator** in a funding project by the Hellenic Association for the Study of the Liver (HASL) entitled: «DNA methylation in PBMCs of patients with autoimmune hepatitis and primary biliary cirrhosis» (6/2019-6/2021).
85. **Participant principal investigator** in a retrospective study entitled: “Outcomes for patients living with primary biliary cholangitis – a retrospective international registry study” (Global PBC Study Group, 2019 – now).
86. **Participant principal investigator** in a study entitled: “Establishment of a Euroean Reference Network database on rare liver diseases (R-LIVER)” (RARE LIVER EC, 2019 – now).
87. **Participant principal investigator** in a retrospective study entitled: “Prognostic value of liver stiffness assesed by fibroscan in primary biliary cholangitis: an international retrospective validation study” (Global PBC Study Group, 2019 – now).
88. **Principal investigator/co-ordinator** in a retrospective study entitled: “The significance of IgM in PBC patients” (Global PBC Study Group, 2019 – now).
89. **Principal investigator/co-ordinator** in a retrospective study entitled: “Prevalence and significance of extrahepatic autoimmune diseases in PBC” (Global PBC Study Group, 2019 – now).
90. **Participant principal investigator** in a phase III study entitled: “A 52-week, placebo-controlled, randomised, Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with primary biliary cholangitis and an inadequate response to or an intolerance to UDCA” (CB8025-31735, 2019 – 2020).
91. **Participant principal investigator** in a phase IV study entitled: “Tenofovir alafenamide in chronic hepatitis B: A Hellenic multicenter ReAl-life Clinical Study” (HERACLIS-TAF, 2019 – now).
92. **Participant principal investigator** in a multicenter retrospective study entitled: “Assessment of the risk of hepatocellular cancer development” (2019 – now).
93. **Participant principal investigator** in a phase II study entitled: “A Phase 2, Double-Blind, Randomized, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid, Administered Alone or in Combination with Bezafibrate, in Subjects with Primary Biliary Cholangitis who had an Inadequate Response or who were Unable to Tolerate Ursodeoxycholic Acid” (INTERCEPT 747-213, 2019 – now).

94. **Collaboration** with Prof. D. Bertsimas, MIT, Boston, USA in a retrospective study entitled: “COVID-19 personalized risk prediction: A machine learning approach” (2020).
95. **Participant principal investigator** in a retrospective study entitled: “Serum glycomics as diagnostic biomarkers in primary biliary cholangitis” (Global PBC Study Group, 2020-now).
96. **Collaboration** with Prof. J. Banales, San Sebastian, Spain in the project entitled: “Extracellular vesicles (EVs) and miRNAs in Patients with Primary Biliary Cholangitis (PBC)” (2020-now).
97. **Participant principal investigator** in a retrospective study entitled: “Multinational retrospective chart review study to assess the characteristics, treatment outcomes and resource use among adult patients hospitalized for community-acquired pneumonia (CAP) and complicated skin and soft tissue infections (CSSTI) treated with zinfo (ceftalorine fosamil) in a usual care setting herein after referred to as "Study" (C2661041, 2020-now).
98. **Participant principal investigator** in a prospective study entitled: “SUPAR guided anakinra treatment for validation of the risk and early management of severe respiratory failure by Covid-19: The save open label, non-randomized single arm trial” (SAVE, 2020).
99. **Participant principal investigator** in a prospective phase IIA study entitled: “Efficiency in management of organ dysfunction associated with infection by the novel SARS-COV-2 virus (COVID-19) through a personalized immunotherapy approach: the escape clinical trial” (ESCAPE, 2020).
100. **Participant principal investigator** in a prospective phase II study entitled: “ITHACA: A phase 2, randomized, single-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of the complement C3 inhibitor, AMY-101, in COVID-19 patients with acute respiratory distress syndrome (ARDS)” (2020-2021).
101. **Participant principal investigator** in a prospective phase III study entitled: “Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of FE 999324 for the Prevention of Recurrent Clostridioides Difficile Infection in Adults” (Syneos 7013442, 2020-now).
102. **Principal investigator/co-ordinator** in a prospective Greek study entitled: “Immune intervention for the management of patients with COVID-19-related pneumonia: An Open Label, Non-Randomised Retrospective/Prospective Observational Study” (2020-2021).
103. **Participant principal investigator** in a multicentre study entitled: “Personalized immunotherapy in sepsis: a multicentre and multinational, double-blind, double-dummy randomized clinical trial” (The IMMUNOSEP trial, 2020-now).
104. **Participant principal investigator** in a multicentre study entitled: “Semaglutide efficacy in non-cirrotic patients with NASH” (NN9931-4553, ESSENCE, 2020-now).
105. **Participant principal investigator** in a multicentre study entitled: “An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)” (CB8025-31731, 2020-now).
106. **Participant principal investigator** in a prospective phase III study entitled: “A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)” (CB8025-32048, 2020-now).
107. **Participant principal investigator** in a prospective phase III study entitled: “Supar guided anakinra treatment for validation of the risk and early management of severe respiratory failure by Covid-19: The save-more double blind, randomized, phase III confirmatory trial” (SAVE-MORE, 2021).

108. **Reviewer for Research Projects in Gastroenterology and Hepatology on behalf of the Hellenic (Greek) Central Council of Health** (*Committee of Biomedical Research*).
109. **Reviewer for Research Projects on behalf of the Hellenic (Greek) Ministry of Education.**
110. **Member of the Scientific Committee for the Prevention, Diagnosis, Management and Treatment of Viral Hepatitis, Hellenic (Greek) Center for Disease Control and Prevention (now National Public Health Organization), Hellenic Ministry of Health (2000-now).**
111. **Associate member of the Governing Board of the Hellenic (Greek) Center for Disease Control and Prevention, Hellenic Ministry of Health (2002-2005).**
112. **Member of the Research Committee of the Hellenic (Greek) Association for the Study of the Liver (2002-03, 2005-07 και 2013-19).**
113. **Vice President of the Committee for the Control of Infectious Diseases** in the University Hospital of Larissa, Greece (2004-2007).
114. **Member of the Advisory Board Examination for Internal Medicine Specialty, Larissa, Greece (2008-2017).**
115. **Member of the Governing Board of the Hellenic (Greek) Association for the Study of the Liver (2001-2003).**
116. **Member of the Advisory Board (Wave III) on “Chronic Hepatitis B: Further understanding hepatitis B in Greece-Regional perspectives & treatment paradigms”, BMS, Thessaloniki, Greece, January 19, 2007.**
117. **Member of the Data Safety Monitoring Board of the German Bundesministry of Education and Research for the GAHB-Study.**
118. **President of the Organizing Committee of the Annual or Biennial International Congress of Internal Medicine, Larissa or Athens, Greece (2009 – now).**
119. **President of the Organizing Committee of the Annual or Biennial Autumn Days of Internal Medicine, Greece (2008-now).**
120. **Member of the Advisory Board on “Facing reality: Effective long term management strategies in patients with CHB in Greece”, BMS, Athens, September 21, 2011.**
121. **Member of the Advisory Board on “Clinical benefit and value assessment of Chronic Hepatitis B long-term patient management strategies in Greece-2012”, BMS, Thessaloniki, June 21, 2012.**
122. **Member of the Advisory Board on “Management of hyperlipidemia, therapeutic targets and the unmet medical needs”, Amgen, Athens, September 11, 2013.**
123. **Member of the Advisory Board on “HCV – The unmet need”, Gilead, Athens, October 24, 2013.**
124. **Member of the Advisory Board on “Long term patient management considerations in HBV in Greece: An evolving landscape”, BMS, Thessaloniki, November 12, 2013.**
125. **Member of the Advisory Board on “Hepatitis B – Post AASLD 2013”, Gilead, Athens, November 27, 2013.**
126. **Member of the Advisory Board on «Analyzing new data on the treatment of hepatitis C – determination of the needs and modification of the management of chronically infected patients – treatment access», Abbvie, Athens, February 26, 2014.**
127. **Member of the HCV Multi-country Advisory Board, AbbVie, Madrid, May 16, 2014.**

128. **Recognition (2013)** of the Department of Medicine, the Liver Unit and the Research Laboratory of Internal Medicine, Medical School, University of Thessaly **by the Hellenic (Greek) Center for Disease Control and Prevention as a Specific Center of Rare Diseases (Autoimmune Hepatitis).**
129. **Elected 1st Vice President of the Governing Board of the Internal Medicine Society of Northern Greece (2011-2015).**
130. **Chairman of the Advisory Board and Steering Committee for the publication of the Clinical Practice Guidelines for the Management of Chronic Viral Hepatitis B and C by the Hellenic (Greek) Center for Disease Control and Prevention, Hellenic Ministry of Health (2013).**
131. **Chairman of the Advisory Board and Steering Committee for the publication of the Updated Clinical Practice Guidelines for the Management of Chronic Viral Hepatitis C by the Hellenic (Greek) Center for Disease Control and Prevention, Hellenic Ministry of Health (2014).**
132. **Member of the Clinical Practice Guideline (CPG) Committee for Autoimmune Hepatitis by the European Association for the Study of the Liver (EASL) Governing Board (May, 2014 – Publication No. 187).**
133. **Member of the Advisory Board on «Recording of the disease course of hepatitis C and the use of Simeprevir in clinical practice in Greece», BMS, Athens, July 3, 2014.**
134. **President of the Institute of Internal Medicine and Hepatology, Larissa, Greece (2012-2018).**
135. **Vice President of the Institute of Internal Medicine and Hepatology, Larissa, Greece (2018-now).**
136. **Elected Vice President of the Governing Board of the Hellenic (Greek) Association for the Study of the Liver (2013-2015).**
137. **Vice President (2013-2015) and President (2015-2017) of the Organizing Committee of the Annual Clinical School of Hepatology by the Hellenic (Greek) Association for the Study of the Liver.**
138. **Member of the Advisory Board on «1st HCV Access», BMS, Athens, October 8, 2014.**
139. **Member of the Advisory Board on «Chronic Hepatitis C – Newer Perspectives», Gilead, Athens, October 10, 2014.**
140. **Invited Faculty Member of the 22nd United European Gastroenterology Week, Vienna, October 18-22, 2014.**
141. **Invited Faculty Poster Reviewer and Speaker in the 22nd United European Gastroenterology Week, Vienna, October 18-22, 2014.**
142. **Member of the International Scientific Committee of the National Organization of Medicines of Greece (October 2014-now).**
143. **Member of the First International Quality Control for Quantification of HDV Viral Load, October 2014.**
144. **Member of the Advisory Board on «Evaluation of newer data on the treatment of HCV infection which have been reported in AASLD 2014 and the treatment options of sofosbuvir/ledipasvir combination», Gilead, Athens, December 10, 2014.**
145. **Member of the HCV International Advisory Board, AbbVie, Rome, January 22, 2015.**
146. **Member of the Advisory Board on «Current positioning of Telbivudine in chronic hepatitis B treatment algorithm», Novartis, Thessaloniki, February 11, 2015.**

147. **Elected 2nd Vice President of the Governing Board of the Internal Medicine Society of Northern Greece now known as Internal Medicine Society of Greece which is official member of the European Federation of Internal Medicine (2015-2018).**
148. **Chairman of the panel member of the Hellenic (Greek) Clinical Practice Guidelines of Autoimmune Hepatitis published by the Hellenic Association for the Study of the Liver (April 2015).**
149. **President of the Governing Board of the Hellenic (Greek) Association for the Study of the Liver (2015-2017).**
150. **Panel member of the Hellenic (Greek) Clinical Practice Guidelines on the Prevention and Treatment of HBV Reactivation during or after Immunosuppressive Therapy published by the Hellenic Association for the Study of the Liver (June 2015).**
151. **Member of the Scientific Committee of the Database of Autoimmune Hepatitis on behalf of the Hellenic Association for the Study of the Liver (2015-τώρα).**
152. **Member of the Advisory Board on «Evaluation of newer data on the treatment of HCV infection, which have been reported in EASL 2015 and assessment of reality in Greece», Gilead, Athens, October 5, 2015.**
153. **Invited Member of the Scientific Committee of the 6th Southeast European Conference on Chemotherapy and Infection (SEEC) in conjunction with the 1st Congress of the Mediterranean Society of Chemotherapy and Infection (MEDSOCHEMI) and the 16th Congress of Mediterranean Society of Chemotherapy (MSC), Thessaloniki, November 13-15, 2015.**
154. **Member of the Advisory Board on «Evaluation of newer data on the treatment of HCV infection, which have been reported in AASLD 2015 and treatment issues in Greece», Gilead, Athens, December 9, 2015.**
155. **Chairman of the Advisory Board and Steering Committee for the publication of the first revision on Clinical Practice Guidelines for the Management of Chronic Viral Hepatitis C by the Hellenic (Greek) Center for Disease Control and Prevention, Hellenic Ministry of Health (December 2015).**
156. **Invited Expert Reviewer for the Foundation for the Development of Internal Medicine in Europe (FDIME) Research Grant Scientific Committee (1/2016-now).**
157. **Individual Collaborator του International Consortium entitled: “European Registry on Autoimmune Hepatitis (ERA)” and Representative of the National Society Partners (Hellenic Society of Gastroenterology and Hellenic Association for the Study of the Liver) of the Consortium (This collaborative initiative 'European Registry on Autoimmune Hepatitis' was granted the UEG LINK award on January 30, 2016).**
158. **Chairman of the Advisory Board and Steering Committee for the publication of the second revision on Clinical Practice Guidelines for the Management of Chronic Viral Hepatitis C by the Hellenic (Greek) Center for Disease Control and Prevention, Hellenic Ministry of Health (April 2016).**
159. **Member of the Advisory Board entitled: “3rd HCV Medical-Access”, BMS, Athens, May 18, 2016.**
160. **Member of the Advisory Board entitled: “Sofosbuvir-based treatment schedules in the treatment of chronic hepatitis C and the European Clinical Practice Guidelines – The option of Tenofovir Alafenamide in the treatment of chronic hepatitis B», Gilead, Athens, October 21, 2016.**
161. **Member of the Advisory Board on «Recording the clinical management of HCV, HCV-related cirrhosis and the specific characteristics of HCV patients in Greece», National School of Public Health, Athens, December 19, 2016.**

162. **Chairman of the panel member of the Hellenic (Greek) Clinical Practice Guidelines of the Use of New Antivirals in Chronic Viral Hepatitis C published by the Hellenic Association for the Study of the Liver (January 2017).**
163. **Chairman of the Advisory Board and Steering Committee for the publication of the third revision on Clinical Practice Guidelines for the Management of Chronic Viral Hepatitis C by the Hellenic (Greek) Center for Disease Control and Prevention, Hellenic Ministry of Health (February 2017).**
164. **Board member of the Committee for the Development of National Strategies against Viral Hepatitis Viruses in Greece (Ministry of Health, April 2017).**
165. **Faculty Member of the 16th European Congress of Internal Medicine, European Federation of Internal Medicine, Milan, Italy, 31 August – 2 September, 2017.**
166. **Member of the Local Organizing Committee of the Stroke Summer School of ESO, Larissa/Leptokarya, September 10-15, 2017.**
167. **Member of the National Organizing and Scientific Committee of the ATHENA 2017 International Conference, Athens, November, 28-30, 2017.**
168. **Board Member of the Steering Committee for the publication of the revised Clinical Practice Guidelines for the Management of Chronic Viral Hepatitis B by the Hellenic (Greek) Center for Disease Control and Prevention, Hellenic Ministry of Health (December 2017).**
169. **Invited Expert Reviewer for the Italian Ministry of Education, Universities and Research (MIUR) (3/2018-now).**
170. **Reviewer of abstracts on behalf of the European Federation of Internal Medicine (EFIM, 16th and 17th European Congress of Internal Medicine 2017 and 2018).**
171. **Faculty Member of the 17th European Congress of Internal Medicine, European Federation of Internal Medicine, Wiesbaden, Germany, 30 August – 1 September, 2017.**
172. **Member of the 2nd Mackay International Meeting on PBC, Lugano, Switzerland, September 23-25, 2018.**
173. **Invited Faculty Member, Chair and Speaker of the 26nd United European Gastroenterology Week, Vienna, October 20-24, 2018.**
174. **Invited Faculty Poster Reviewer of the 26nd United European Gastroenterology Week, Vienna, October 20-24, 2018.**
175. **Member of the Advisory Board entitled: “Therapeutic management of patients with advance hepatocellular cancer”, IPSEN, Athens, December 8, 2018.**
176. **Member of the Working Group of IAIHG entitled: “Definitions on endpoints in AIH” (December 2018).**
177. **Chairman of the panel member of the Revised Clinical Practice Guidelines of Autoimmune Hepatitis of the Hellenic (Greek) Association for the Study of the Liver (January 2019 – Publication No. 226).**
178. **Member of the Advisory Board and Steering Committee for the publication of the forth revision on Clinical Practice Guidelines for the Management of Chronic Viral Hepatitis C by the Hellenic (Greek) Center for Disease Control and Prevention, Hellenic Ministry of Health (February 2019).**
179. **Member of the Local Scientific Committee and Chairman of Meet the Experts in the Advanced Learning on Platelets & Thrombosis International Course (ALPIC 2019),**

- European and Mediterranean League Against Thrombotic Diseases**, Metsovo, March 22-24, 2019.
180. **Faculty Member** of the **18th European Congress of Internal Medicine**, European Federation of Internal Medicine, Lisbon, Portugal, August 29-31, 2019.
 181. **Member of the Educational Committee of the the Hellenic (Greek) Association for the Study of the Liver** (6/2019-6/2021).
 182. **Official Recognition by the Ministry of Health (FEK Part B'4040/05.11.2019)** of the **Department of Medicine and Research Laboratory of Internal Medicine of the General University Hospital of Larissa as National Expertise Center of Greece in Autoimmune Liver Diseases (Director: Prof. G.N. Dalekos)**.
 183. **Faculty Member** of the **EASL International Liver Congress 2020**, European Association for the Study of the Liver, London, UK, April 14-19, 2020.
 184. **Member of the Advisory Board** entitled: **“Positioning Anakinra in Covid-19: prevention and/or treatment of severe respiratory failure”**, Sobi, Webinar, September 18, 2020.
 185. **Invited Faculty Member and Speaker** of the **19th European Congress of Internal Medicine**, European Federation of Internal Medicine, Virtual Congress, March 18-20, 2021.

BIBLIOGRAPHY

A. Thesis

Doctoral Thesis

«*Inflammatory Bowel Disease: Immunologic abnormalities*», Ioannina, 1995.

Parts of my Doctoral Thesis have been published as full papers in *Gut*, *European Journal of Internal Medicine* and *European Journal of Gastroenterology and Hepatology* (see International Publications No: 1,4,19 and 28).

B. Papers in International Medical Journals

1. **G.N. Dalekos**, M.N. Manoussakis, A.C. Goussia, E.V. Tsianos, H.M. Moutsopoulos. Soluble interleukin-2 receptors, antineutrophil cytoplasmic antibodies, and other autoantibodies in patients with ulcerative colitis. *Gut* 34: 658-664, 1993.
2. **G.N. Dalekos**, M.N. Manoussakis, E. Zervou, E.V. Tsianos, H.M. Moutsopoulos. Immunologic and viral markers in the circulation of anti-HIV negative heroin addicts. *Eur J Clin Invest* 23: 219-225, 1993.
3. E.V. Tsianos, **G.N. Dalekos**, M. Elisaf, E. Zervou, K.C. Siamopoulos. High frequency of antibodies to Hantaan virus and hepatitis C virus in haemodialysis patients. Coincidence or cross reaction? *J Intern Med* 234: 607-610, 1993.
4. E.V. Tsianos, C.N. Masalas, M. Merkouropoulos, **G.N. Dalekos**, R.F. Logan. Incidence of inflammatory bowel disease in north west Greece: Rarity of Crohn's disease in an area where ulcerative colitis is common. *Gut* 35: 369-372, 1994.
5. **G.N. Dalekos**, E.V. Tsianos: Antineutrophil antibodies in chronic viral hepatitis. *J Hepatol (Letter)* 20: 561, 1994.
6. E.V. Tsianos, **G.N. Dalekos**, M.H. Merkouropoulos, A. Tsatsoulis, K.I. Seferiadis. Frequency of thyroid dysfunction after recombinant alpha-interferon therapy in Greek patients with chronic active hepatitis. *Eur J Gastroenterol Hepatol* 6: 547-551, 1994.

7. **G.N. Dalekos**, G.C. Liapi, P. Dallas, D. Stefanou, M. Elisaf: Stauffer's syndrome as first manifestation of renal cell carcinoma. A case report. *Eur J Intern Med* 5: 319-320, 1994.
8. E.V. Tsianos, **G.N. Dalekos**, C. Tzermias, M.H. Merkouropoulos, J. Hatzis. Hidradenitis suppurativa in Crohn's disease. A further support to this association. *J Clin Gastroenterol* 20: 151-153, 1995.
9. P.G. Vlachoyiannopoulos, **G.N. Dalekos**, A. Tsatsoulis: Transient hyperthyroidism following lower respiratory tract infections. A clinical observation. *Eur J Intern Med* 6: 19-22, 1995.
10. **G.N. Dalekos**, E. Zervou, E.V. Tsianos. IgM antibodies to HCV in chronic active hepatitis in NW Greece. Solution or more questions? *J Hepatol (Letter)* 22: 509, 1995.
11. **G.N. Dalekos**, E. Zervou, F. Karabini, K. Bourantas, M. Elisaf, K.C. Siamopoulos. Prevalence of antibodies to human T-lymphotropic virus types I and II in volunteer blood donors and high risk groups in northwestern Greece. *Transfusion* 35: 503-506, 1995.
12. **G.N. Dalekos**, E. Zervou, F. Karabini, E.V. Tsianos. Prevalence of viral markers among refugees from southern Albania: increased incidence of infections with hepatitis A, B and D viruses. *Eur J Gastroenterol Hepatol* 7: 553-558, 1995.
13. C. Tzermias, **G.N. Dalekos**, J. Hatzis, E.V. Tsianos: Pyoderma gangrenosum: successful treatment with intralesional injections of corticosteroids. *J Eur Acad Dermatol Venerol (Letter)* 5: 197-199, 1995.
14. A. Tsatsoulis, P.G. Vlachoyiannopoulos, **G.N. Dalekos**, E.O. Johnson, H.M. Moutsopoulos. Increased serum interleukin-1 β (IL-1 β) during treatment of hyperthyroidism with antithyroid drugs. *Eur J Clin Invest* 25: 654-658, 1995.
15. **G.N. Dalekos**, F.N. Skopouli, E.V. Tsianos. Primary biliary cirrhosis associated with anticardiolipin syndrome. *Eur J Intern Med* 6: 179-181, 1995.
16. **G.N. Dalekos**, E. Zervou, M.H. Merkouropoulos, E.V. Tsianos. Prevalence of hepatitis B and C viruses infection in chronic alcoholics with or without liver disease in Ioannina, Greece: Low incidence of HCV infection. *Eur J Epidemiol* 12: 21-25, 1996.
17. N.V. Angelopoulos, Chr. Mantas, **G.N. Dalekos**, K. Vasalos, E.V. Tsianos. Psychiatric factors in patients with ulcerative colitis according to disease activity. *Eur J Psychiat* 10: 87-99, 1996.
18. **G.N. Dalekos**, C. Papas, L.G. Christou, J. Pneumaticos, G. Nakos. Severe erysipelas in a previously healthy man: possible link with Epstein-Barr virus infection. *Eur J Intern Med* 7: 53-56, 1996.
19. **G.N. Dalekos**, E.V. Tsianos, H.M. Moutsopoulos. Immunologic markers of disease activity in the circulation of patients with ulcerative colitis: high concentrations of soluble interleukin-2 receptor molecules and interleukin-6 in active disease. *Eur J Intern Med* 7: 93-98, 1996.
20. **G.N. Dalekos**, M. Elisaf, N. Papagalanis, Chr. Tzallas, K.C. Siamopoulos. Elevated interleukin-1 β in the circulation of patients with essential hypertension before any drug therapy: A pilot study. *Eur J Clin Invest* 26: 936-939, 1996.
21. **G.N. Dalekos**, E. Zervou, K. Bourantas, E.V. Tsianos. Viral hepatitis and idiopathic (autoimmune) thrombocytopenic purpura. Is there any relationship? *J Hepatol (Letter)*, 25: 1000-1001, 1996.
22. S. Shivananda, J Lennard-Jones, R. Logan, N. Fear, A. Price, L. Carpenter, M. van Blankenstein, S. Shivananda, J Lennard-Jones, R. Logan, N. Fear, A. Price, L. Carpenter, M. van Blankenstein, S. Bjornsson, J.H. Johansson, E. Oddsson, B. Moum, M. Vatn, E. Aadland, O. Fausa, I. Lygren, J. Sauar, T. Schulz, N. Stray, R. Stave, E. Langholz, V. Binder, P. Vedtofte, J. Sonne, R. Collins, C. Omorain, J. Mayberry, I. Carr, M. Russel, R. Stockbrugger, H. Goebell, B. Katschinski-Breuer, J.L. Dupas, P. Bianchi, T. Ranzi, M.C. Campannini, M.

- Curzio, R. Gullotta, P. Bodoni, P. Politi, G. Lupinacci, A. Zambelli, G. Fornaciari, M. Beltrami, M.G. Mortilla, F. Nicoli, L. Serra, G. Trallori, A. Bonanomi, G. dAlbasio, F. Pacini, V.R. Ochoa, A. delaFuente, F. Tardaguila, D.D. Rodriguez, S. Pereira, D.M. Butron, D.M. Cueto, L. Alvarez Cervea, J. Clofent, J.R. Pineda, E. Brullet, X. Bonfill, G. Urrutia, F.T. Veloso, R. Noronha, E. Tsianos, **G. Dalekos**, E. Monteiro, J. Freitas, P. Borralho, F.C. Leal, C. Soares, P. Martins, M. Dupond, M. Cottone, G. Filippazzo, R. Ayala, J. Mouzas, O. Manousos, S. Odes, R. Brower, J. Campbell, R. Doll, A. Ekbom. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative study on Inflammatory Bowel Disease (EC-IBD). *Gut* 39: 690-697, 1996.
23. **G.N. Dalekos**, M. Elisaf, E. Bairaktari, O. Tsolas, K.C. Siamopoulos. Increased serum levels of interleukin-1 β in the systemic circulation of patients with essential hypertension: additional risk factor for atherogenesis in hypertensive patients? *J Lab Clin Med (now Transl Res)* 129: 300-308, 1997. (Original article with Editorial).
24. K.L. Bourantas, L.G. Christou, **G.N. Dalekos**, K. Barbati, E.V. Tsianos. A 54-year-old stock-breeder with ascites. *Lancet* 349: 994, 1997.
25. J. E. Lennard-Jones, S. Shivananda, N. Fear, L. Carpenter, M. van Blankenstein, S. Bjornsson, J.H. Johansson, E. Oddsson, B. Moum, M. Vatn, E. Aadland, O. Fausa, I. Lygren, J. Sauar, T. Schulz, N. Stray, R. Stave, E. Langholz, V. Binder, P. Vedtofte, J. Sonne, R. Collins, C. Omorain, J. Mayberry, I. Carr, M.G.V.M. Russel, R. Stockbrugger, H. Goebell, B. Katschinski-Breuer, J.L. Dupas, P. Bianchi, T. Ranzi, M.C. Campannini, M. Curzio, R. Gullotta, P. Bodoni, P. Politi, G. Lupinacci, A. Zambelli, G. Fornaciari, M. Beltrami, M.G. Mortilla, F. Nicoli, L. Serra, G. Trallori, A. Bonanomi, G. dAlbasio, F. Pacini, V.R. Ochoa, A. delaFuente, F. Tardaguila, D.D. Rodriguez, S. Pereira, D.M. Butron, D.M. Cueto, L. Alvarez Cervea, J. Clofent, J.R. Pineda, E. Brullet, X. Bonfill, G. Urrutia, F.T. Veloso, R. Noronha, E. Tsianos, **G. Dalekos**, E. Monteiro, J. Freitas, P. Borralho, F.C. Leal, C. Soares, P. Martins, M. Dupond, M. Cottone, G. Filippazzo, R. Ayala, J. Mouzas, O. Manousos, S. Odes, R. Brower, J. Campbell, R. Doll, A. Ekbom, Logan RF, Price AB. Clinical uniformity of inflammatory bowel disease at presentation and during the first year of disease in the north and south of Europe. *Eur J Gastroenterol Hepatol* 9: 353-359, 1997.
26. **G.N. Dalekos**, J. Hatzis, E.V. Tsianos. Dermatologic disease during interferon-alpha therapy for chronic viral hepatitis. *Ann Intern Med (Letter)* 128: 409-410, 1998.
27. M.G.V.M. Russel, A. Volovics, E.J. Schoon, E.H.J. van Wijlick, R.F. Logan, S. Shivananda, R. Stockbrugger, E. Langholz, V. Binder, J.L. Dupas, H. Goebell, B. Katschinski-Breuer, E. Tsianos, **G. Dalekos**, J. Mouzas, O. Manousos, S. Bjornsson, E. Oddsson, S. Odes, C. O'Morain, R. Collins, P. Bianchi, T. Ranzi, P. Bodoni, P. Politi, M. Cottone, G. Fornaciari, M. Beltrami, G. Trallori, A. Bonanomi, M. Vatn, B. Moum, F.T. Veloso, R. Noronha, E. Monteiro, J. Freitas, E. Brullet, X. Bonfill, V.R. Ochoa, A. de la Fuente, J. Mayberry, I. Carr. Inflammatory bowel disease: Is there any relation between smoking status and disease presentation? *Inflamm Bowel Dis* 4: 182-186, 1998.
28. **G.N. Dalekos**, J. Ringstad, J. Savaidis, K.I. Seferiadis, E.V. Tsianos. Zinc, copper and immunologic markers in the circulation of well-nourished patients with ulcerative colitis. *Eur J Gastroenterol Hepatol* 10: 331-337, 1998.
29. **G.N. Dalekos**, E. Zervou, M. Elisaf, N. Germanos, K. Bourantas, E. Galanakis, K.C. Siamopoulos, E.V. Tsianos. Antibodies to hepatitis E virus among different populations in Greece: increased prevalence in an haemodialysis unit. *Transfusion* 38: 595-598, 1998.
30. **G.N. Dalekos**, D.S. Boumba, K. Katopodis, E. Zervou, G. Sferopoulos, M. Elisaf, E.V. Tsianos, K.C. Siamopoulos. Absence of viraemia due to HCV in anti-HCV negative haemodialysis patients. *Nephrol Dial Transpl* 13: 1804-1806, 1998.

31. K.L. Bourantas, **G.N. Dalekos**, A. Makis, A. Chaidos, S. Tsiara, A. Mavridis. Acute phase proteins and interleukins in steady state sickle cell disease. *Eur J Haematol* 61: 49-54, 1998.
32. **G.N. Dalekos**, K. Achenbach, D. Christodoulou, G.K. Liapi, E. Zervou, D. Sideris, E.V. Tsianos. Idiopathic dilated cardiomyopathy: lack of association with hepatitis C virus infection. *Heart* 80: 270-275, 1998.
33. **G.N. Dalekos**, D. Christodoulou, K. G. Kistis, J. Hatzis, E.V. Tsianos. A prospective evaluation of dermatologic side effects during interferon-alpha therapy for chronic viral hepatitis. *Eur J Gastroenterol Hepatol* 10:933-939, 1998.
34. **G.N. Dalekos**, E. Zervou, M. Elisaf, D.S. Boumba, K. Katopodis, G. Sferopoulos, K.C. Siamopoulos, E.V. Tsianos. Increased prevalence of markers of GBV-C/HGV infection in a selected cohort of haemodialysis patients negative for other blood-borne viruses. *Nephrol Dial Transpl (Letter)*,14: 255-256, 1999.
35. **G.N. Dalekos**, H. Wedemeyer, P. Obermayer-Straub, A. Kayser, A. Barut, H. Frank, M.P. Manns. Epitope mapping of cytochrome P450 2D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment. *J Hepatol* 30: 366-375, 1999.
36. M. Fatouros, **G.N. Dalekos**, E. Mylonakis, G. Vekinis, A. Kapas. Alterations in body weight, breaking strength and wound healing in Wistar rats treated pre- and postoperatively with erythropoietin or granulocyte-macrophage colony stimulating factor: Evidence of a previously unknown anabolic effect of erythropoietin? *J Lab Clin Med (now Transl Res)* 133: 253-259, 1999.
37. **G.N. Dalekos**, K. Kistis, D. Boumba, E. Zervou, P. Voulgari, A.A. Drosos, E.V. Tsianos. Increased incidence of anticardiolipin antibodies in patients with hepatitis C is not associated with aetiopathogenetic link to antiphospholipid syndrome. *Eur J Gastroenterol Hepatol* 12: 67-74, 2000.
38. **G.N. Dalekos**, E. Galanakis, E. Zervou, M. Tzoufi, P.L. Lapatsanis, E.V. Tsianos. Interferon-alpha treatment of children with hepatitis D virus infection: The Greek experience. *Hepatogastroenterology*, 47: 1072-1076, 2000.
39. E.K. Zervou, **G.N. Dalekos**, D.S. Boumba, E.V. Tsianos. Value of anti-HBc screening of blood donors for prevention of HBV infection: Results of a three year prospective study in northwestern Greece. *Transfusion*, 41: 652-658, 2001.
40. **G.N. Dalekos**, K. Zachou, Ch. Liaskos. The antiphospholipid syndrome and infection. (**Invited review**). *Curr Rheumatol Reports*, 3: 277-285, 2001.
41. D.K. Christodoulou, **G.N. Dalekos**, M. Merkouropoulos, K.G. Kistis, G. Georgitsi, E. Zervou, K. Zachou, E.V. Tsianos. Cryoglobulinemia due to chronic viral hepatitis infections is not a major problem in clinical practice. *Eur J Intern Med*, 12: 435-441, 2001.
42. P. Obermayer-Straub, S. Braun, A. Kayser, A. Barut, S. Loges, A. Harms, C. Strassburg, **G. Dalekos**, J. Perheentupa, M.P. Manns. Hepatic autoantigens in patients with autoimmune polyendocrine syndrome type 1 (APS1). *Gastroenterology* 121:668-677, 2001.
43. **G.N. Dalekos**, E. Makri, S. Loges, P. Obermayer-Straub, K. Zachou, Th. Tsirikas, E. Schmidt, G. Papadamou, M.P. Manns. Increased incidence of anti-LKM autoantibodies in a consecutive cohort of HCV patients from central Greece. *Eur J Gastroenterol Hepatol* 14:35-42, 2002.
44. **G.N. Dalekos**, K. Zachou, C. Liaskos, N. Gatselis. Autoantibodies and defined target-autoantigens in autoimmune hepatitis: An overview. *Eur J Intern Med* 13:293-303, 2002.
45. K. Zachou, C. Liaskos, D.K. Christodoulou, M. Kardasi, G. Papadamou, N. Gatselis, S.P. Georgiadou, E.V. Tsianos and **G.N. Dalekos**. Anti-cardiolipin antibodies in patients with

chronic viral hepatitis are independent of beta2-glycoprotein I co-factor or features of antiphospholipid syndrome. *Eur J Clin Invest* 33:161-168, 2003.

46. E. Zervou, D.S. Boumba, Ch. Liaskos, S. Georgiadou, E.V. Tsianos, **G.N. Dalekos**. Low prevalence of HCV, HIV and HTLV-I/II infection markers in northwestern Greece: Results of a three year prospective donor study. *Eur J Intern Med* 14:39-44, 2003.
47. A. Polyzos, C. Sinani, N. Kelekis, G. Papadamou, K. Patsiaoura, and **G.N. Dalekos**. Advanced-stage intrahepatic cholangiocarcinoma in a patient with end-stage HCV-associated liver disease. *Eur J Gastroenterol Hepatol* 15:331-334, 2003.
48. D.S. Kyriakou, M.G. Alexandrakis, K. Zachou, F. Passam, N.E. Stathakis and **G.N. Dalekos**. Hemopoietic progenitor cells and bone marrow stromal cells in patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. *J Hepatol* 39:679-685, 2003.
49. **G.N. Dalekos**, P. Obermayer-Straub, M. Bartels, T. Maeda, A. Kayser, S. Loges, S. Braun, E. Schmidt, M.E. Gershwin, M.P. Manns. Cytochrome P450 2A6: A new hepatic autoantigen in chronic hepatitis C virus infection. *J Hepatol* 39:800-806, 2003. (**Original article with Editorial**).
50. K. Zachou, E. Rigopoulou, C. Liaskos, K. Patsiaoura, E. Makri, N. Stathakis, and **G.N. Dalekos**. Primary biliary cirrhosis presented as peripheral eosinophilia in asymptomatic women with or without elevated alkaline phosphatase. *Eur J Gastroenterol Hepatol* 16:425-428, 2004.
51. N. Kelekis, E. Makri, A. Vasiou, K. Patsiaoura, M. Spiridakis and **G.N. Dalekos**. Confluent hepatic fibrosis as the presenting imaging sign in non-advanced alcoholic cirrhosis. *Clin Imaging* 28:124-127, 2004.
52. S.P. Georgiadou, K. Zachou, C. Liaskos, E. Rigopoulou, F. Gerovasilis, E. Makri, **G.N. Dalekos**. Occult hepatitis B virus (HBV) infection in Greek patients with chronic hepatitis C and diverse non-viral hepatic diseases. *J Viral Hepat* 11:358-365, 2004.
53. E. Rigopoulou, **G.N. Dalekos**. Anti-sp100 antibodies in primary biliary cirrhosis. *Scand J Gastroenterol* 39:406-407, 2004.
54. A.N. Moulas, A. Noulas, E. Makri, S. Bonanou-Tzedaki, and **G.N. Dalekos**. Total antioxidant status and erythrocyte superoxide dismutase activity in patients with chronic hepatitis B and C. *Eur J Inflamm* 2:77-84, 2004.
55. K. Zachou, E. Rigopoulou, and **G.N. Dalekos**. Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. *J Autoim Dis* 1:2, 2004 (15 October 2004) (**Invited Review; this article has qualified as 'Highly accessed'; Accesses 42155 up to 31-12-2018**).
56. E. E. Yiannaki, E. Zintzaras, A. Analatos, C. Theodoridou, **G.N. Dalekos**, A.E. Germenis. Evaluation of a microsphere-based flow cytometric assay for diagnosis of celiac disease. *J Immunoassay Immunochem* 25:345-357, 2004.
57. I. Stefanidis, E.K. Zervou, Ch. Rizos, Ch. Syrganis, E. Patsidis, G. Kyriakopoulos, L. Sdrakas, N. Tsianos, Rigopoulou EI, Liakopoulos V, **G.N. Dalekos**. Hepatitis E virus antibodies in hemodialysis patients: an epidemiological survey in central Greece. *Int J Artif Organs* 27:842-847, 2004.
58. E.K. Zervou, S. Georgiadou, M. Tzilianos, P. Georgitsi, V. Pournara, S. Nousis, C. Pappas, L. Daskalou, A. Vrettou, F. Karabini, and **G.N. Dalekos**. Human T-lymphotropic virus type-I/II infections in volunteer blood donors of north and west Greece. *Eur J Intern Med* 15:422-427, 2004.
59. N.K. Gatselis, S.P. Georgiadou, N. Tassopoulos, K. Zachou, C. Liaskos, A. Hatzakis, and **G.N. Dalekos**. Impact of parietal cell autoantibodies (PCA) and non-organ specific autoantibodies

- (NOSA) on the treatment outcome of patients with HCV infection: a pilot study. *World J Gastroenterol* 11:482-487, 2005.
60. A. Tsirikoni, D.S. Kyriakou, E.I. Rigopoulou, M.G. Alexandrakis, K. Zachou, F. Passam, **and G.N. Dalekos**. Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. *J Hepatol* 42:393-399, 2005.
 61. E.I. Rigopoulou, E.T. Davies, A. Pares, K. Zachou, C. Liaskos, D.P. Bogdanos, J. Rodes, **G.N. Dalekos**, D. Vergani. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. *Gut* 54:528-532, 2005.
 62. C. Liaskos, E. Rigopoulou, K. Zachou, S. Georgiadou, N. Gatselis, **and G.N. Dalekos**. Prevalence and clinical significance of anticardiolipin antibodies in patients with autoimmune hepatitis type 1. *J Autoimmun* 24:251-260, 2005.
 63. A. Stefos, S.P. Georgiadou, C. Gioti, A. Loukopoulos, M. Ioannou, S. Pournaras, **and G.N. Dalekos**. Leptospirosis and pancytopenia: Two case reports and review of the literature. *J Infection* 51:e277-280, 2005.
 64. M. Satra, **G.N. Dalekos**, P. Kollia, N. Vamvakopoulos, A. Tsezou. Telomerase reverse transcriptase mRNA expression in peripheral lymphocytes of patients with chronic HBV and HCV infections. *J Viral Hepat* 12:488-493, 2005.
 65. E.K. Zervou, S.P. Georgiadou, G.K. Liapi, F. Karabini, V. Giogiakas, K. Zisiadis, N.K. Gatselis, I. Goudevenos **and G.N. Dalekos**. Hepatitis viruses and human T-lymphotropic virus type I/II infection markers in patients underwent an open-heart surgery: Evidence of increased risk for exposure to HBV and HEV. *Eur J Intern Med* 16:424-428, 2005.
 66. E.K. Zervou, N.K. Gatselis, E. Xanthi, K. Ziciadis, **and G.N. Dalekos**. Intrafamilial spread of hepatitis B virus infection in Greece. *Eur J Gastroenterol Hepatol* 17:911-915, 2005.
 67. E.I. Rigopoulou, I. Stefanidis, C. Liaskos, E.K. Zervou, C. Rizos, P. Mina, K. Zachou, C. Syrganis, E. Patsidis, G. Kyriakopoulos, L. Sdrakas, N. Tsianas **and G. N. Dalekos**. HCV RNA qualitative assay based on transcription-mediated amplification improves the detection of hepatitis C virus infection in patients on hemodialysis: Results from five hemodialysis units in central Greece. *J Clin Virol* 34:81-85, 2005.
 68. A.E. Germanis, E.E. Yiannaki, K. Zachou, V. Roka, S. Barbanis, C. Liaskos, K. Adam, A.N. Kapsoritakis, S. Potamianos, **G.N. Dalekos**. Prevalence and clinical significance of IgA antibodies against tissue transglutaminase in patients with diverse chronic liver diseases. *Clin Diag Lab Immunol (now Clin Vaccine Immunol)* 12:941-948, 2005.
 69. K. Zachou, E. Rigopoulou, A. Tsirikoni, M. Alexandrakis, F. Passam, D. Kyriakou, N. Stathakis **and G.N. Dalekos**. Cytokines production is distinct in bone marrow cultures from patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. *J Autoimmun* 25:283-288, 2005.
 70. I. Stefanidis, V. Liakopoulos, E.I. Rigopoulou, **G.N. Dalekos**. Diagnostic discordance for hepatitis C virus infection in hemodialysis: correlations with clinical and laboratory features. *Am J Kidney Dis (Letter)* 46:992-993, 2005.
 71. I. Nikaina, C. Pastaka, K. Zachou, **G.N. Dalekos**, K. Gourgouljanis. Sleep apnoea syndrome and early stage cirrhosis: a pilot study. *Eur J Gastroenterol Hepatol* 18:31-35, 2006.
 72. N. Gatselis, E. Malli, G. Papadamou, E. Petinaki, **and G.N. Dalekos**. Direct detection of *Cardiobacterium hominis* in serum from a patient with infective endocarditis by broad-range bacterial PCR. *J Clin Microbiol* 44:669-672, 2006.

73. N. Tzovaras, A. Stefos, S.P. Georgiadou, N. Gatselis, G. Papadamou, E. Rigopoulou, M. Ioannou, I. Skoularigis **and G.N. Dalekos**. Reversion of severe hepatopulmonary syndrome in a non-cirrhotic patient after corticosteroid treatment for granulomatous hepatitis: A case report and review of the literature. *World J Gastroenterol* 12:336-339, 2006.
74. H.L. Tillmann, J. Hadem, L. Leifeld, K. Zachou, A. Canbay, C. Eisenbach, I. Graziadei, J. Encke, H. Schmidt, W. Vogel, A. Schneider, U. Spengler, G. Gerken, **G.N. Dalekos**, H. Wedemeyer, M.P. Manns. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. *J Viral Hepat* 13:256-63, 2006.
75. T.A. Zografos, E.I. Rigopoulou, C. Liaskos, E. Togousidis, K. Zachou, N. Gatselis, A. Germanis **and G. N. Dalekos**. Alterations of leptin during IFN-a therapy in patients with chronic viral hepatitis. *J Hepatol* 44:848-55, 2006.
76. Zachou K, Liaskos C, Rigopoulou E, Gabeta S, Papamichalis P, Gatselis N, Georgiadou S, **and G.N. Dalekos**. Presence of high avidity anticardiolipin antibodies in patients with autoimmune cholestatic liver diseases. *Clin Immunol* 119:203-212, 2006.
77. E.I. Rigopoulou, S.P. Georgiadou, S. Barbanis, **G.N. Dalekos**. Lack of association between appendectomy and primary biliary cirrhosis (PBC). *Scand J Gastroenterol* 41:573-576, 2006.
78. D.P. Bogdanos, C. Liaskos, E.I. Rigopoulou, **G.N. Dalekos**. Anti-mitochondrial antibodies in patients with systemic lupus erythematosus: revealing the unforeseen. *Clin Chim Acta (Letter)* 373:183-184, 2006.
79. K. Mimidis, V.P Papadopoulos, I. Elefsiniotis, D. Kolioukas, I. Ketikoglou, E. Paraskevas, S. Kanatakis, D. Chrysagis, **G.N Dalekos**, C. Tzathas, A. Protopapas, E. Gigi, E. Tsianos, G. Kartalis. Hepatitis C virus survival curve analysis in naïve patients treated with peg-interferon a-2b plus ribavirin. A randomized controlled trial for induction with high doses of peg-interferon and predictability of sustained viral response from early virologic data. *J Gastrointestin Liver Dis* 15:213-219, 2006.
80. N. Stefanou, M. Satra, V. Papanikolaou, F. Kalala, N. Gatselis, A. Germanis, **G.N. Dalekos**, A. Tsezou. Leptin receptor isoforms mRNA expression in peripheral blood mononuclear cells from patients with chronic viral hepatitis. *Exp Biol Med* 231:1653-1663, 2006.
81. E. Petinaki and **G.N. Dalekos**. Molecular methods as tools for the diagnosis of bacterial infections: useful or useless? *Res Adv Microbiology* 6:23-31, 2006. **(Invited review)**.
82. A.I. Papaioannou, K. Kostikas, N. Tzovaras, T.S. Kiropoulos, A. Loukopoulos, M.G. Ioannou, F. Karasavvidou, **G.N. Dalekos**, K.I. Gourgoulialis. Mantle cell lymphoma presenting with persistent pleural effusion and severe thrombocytopenia. *The Internet Journal of Pulmonary Medicine* 6: 2, 2006.
83. E. Tsironi, N. Gatselis, M.G. Kotoula, D. Z. Chatzoulis, **G.N. Dalekos**. Unexplained choroidal embolization: Remember the antiphospholipid syndrome. *Lancet* 368:1936, 2006.
84. **G.N. Dalekos**, K. Makaritsis, E.I. Rigopoulou. Redesigning training for internal medicine. What needs to be done? *Ann Intern Med (Letter)* 145:865, 2006.
85. P. Guéguen, **G. Dalekos**, J-B Nousbaum, K. Zachou, Putterman C, Youinou P, Renaudineau Y. Double reactivity against actin and α -actinin defines a severe form of autoimmune hepatitis type 1. *J Clin Immunol* 26: 495-505, 2006.
86. N.K. Gatselis, S.P. Georgiadou, G.K. Koukoulis, N. Tassopoulos, K. Zachou, C. Liaskos, A. Hatzakis, **G.N. Dalekos**. Clinical significance of organ and non-organ specific autoantibodies on the response to antiviral treatment of patients with chronic hepatitis C. *Aliment Pharmacol Ther* 24:1563-1573, 2006.

87. M. Satra, N. Gatselis, D. Iliopoulos, D. Zacharoulis, **G.N. Dalekos**, A. Tsezou. Real time quantification of human telomerase reverse transcriptase mRNA in liver tissues from patients with hepatocellular cancer and chronic viral hepatitis. *J Viral Hepat* 14:41-7, 2007.
88. C. Liaskos, D.P. Bogdanos, E.T. Davies, **G.N. Dalekos**. Diagnostic relevance of anti-filamentous actin antibodies in autoimmune hepatitis. *J Clin Pathol (Letter)* 60:107-108, 2007.
89. N.K. Gatselis, E. Rigopoulou, A. Stefos, M. Kardasi, **and G.N. Dalekos**. Risk factors associated with HCV infection in semi-rural areas of central Greece. *Eur J Intern Med* 18:48-55, 2007.
90. E.I. Rigopoulou, M. Mytilinaiou, O. Romanidou, C. Liaskos, **G.N. Dalekos**. Autoimmune hepatitis-specific antibodies against soluble liver antigen and liver cytosol type 1 in patients with chronic viral hepatitis. *J Autoimmune Dis* 4(1): 2, 2007 (**This article has qualified as 'Highly accessed'; Accesses up to 31-12-2018: 15631; see <http://www.jautoimdis.com/content/4/1/2/about>**).
91. C. Liaskos, D.P. Bogdanos, E.I. Rigopoulou, **G.N. Dalekos**. Development of anti-mitochondrial antibodies in patients with autoimmune hepatitis: an art of facts or an artifact? *J Gastroenterol Hepatol (Letter)* 22:454-455, 2007.
92. N.K. Gatselis, A. Stefos, C. Gioti, E.I. Rigopoulou and **G.N. Dalekos**. Primary biliary cirrhosis and Henoch-Schonlein purpura: Report of two cases and review of the literature. *Liver Int* 27:280-283, 2007.
93. A. Daponte, M. Ioannou, C. Gioti, A. Kallitsaris, **G.N. Dalekos**, I.E. Messinis. Primary retroperitoneal non-Hodgkin lymphoma presenting with torturous generalized pruritus in an elderly. *Arch Gynecol Obstet* 275:287-289, 2007.
94. N.K. Gatselis, K. Tepetes, A. Loukopoulos, K. Vasiou, A. Zafirou, C. Gioti, and **G.N. Dalekos**. Hepatitis B virus and intrahepatic cholangiocarcinoma: report of two cases and review of the literature. *Cancer Investigation* 25:55-8, 2007.
95. E.I. Rigopoulou, D-P Bogdanos, C. Liaskos, A. Koutsoumpas, H. Baum, D. Vergani, **and G.N. Dalekos**. Anti-mitochondrial antibody immunofluorescent titres correlate with the number and intensity of immunoblot-detected mitochondrial bands in patients with primary biliary cirrhosis. *Clin Chim Acta* 380:118-21, 2007.
96. E.I. Rigopoulou, **G. Dalekos**, D.P. Bogdanos. How common are connective tissue disorders in patients with autoimmune hepatitis? *Sem Arthritis Rheum (Letter)* 36:332, 2007.
97. D.P. Bogdanos, C. Liaskos, A. Pares, G. Norman, E.I. Rigopoulou, L. Caballeria, **G.N. Dalekos**, J. Rodes, D. Vergani. Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. *Hepatology (Letter)* 45:1583, 2007.
98. S. Gabeta, G.L. Norman, C. Liaskos, P.A. Papamichalis, T. Zografos, A. Garagounis, E.I. Rigopoulou **and G.N. Dalekos**. Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. *J Clin Immunol* 27:378-387, 2007.
99. P.A. Papamichalis, K. Zachou, G.K. Koukoulis, A. Veloni, E.G. Karacosta, L. Kyprilou, I. Mamaloudis, S. Gabeta, E.I. Rigopoulou, A.W. Lohse **and G.N. Dalekos**. The revised international autoimmune hepatitis (AIH) score in chronic liver diseases including AIH/overlap syndromes and AIH with concurrent other liver disorders. *J Autoimmune Dis* 4:3, 2007 (**This article has qualified as 'Highly accessed'; Accesses up to 31-12-2018: 29711; see <http://www.jautoimdis.com/content/4/1/3/about>**).
100. E.I. Rigopoulou, E.T. Davies, D.P. Bogdanos, C. Liaskos, G.K. Koukoulis, **G.N. Dalekos**, P. Vergani. Anti-mitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis. *Liver Int* 27:1226-1231, 2007.

101. T.A. Zografos, C. Liaskos, E.I. Rigopoulou, E. Togousidis, K. Makaritsis, A. Germenis, **and G.N. Dalekos**. Adiponectin: a new independent predictor of liver steatosis and response to IFN- α treatment in chronic hepatitis C? *Am J Gastroenterol* 103:605-614, 2008.
102. E.I. Rigopoulou **and GN Dalekos**. Autoimmune hepatitis: of host and pathogen. *Hepatology (letter)* 47:2147-2148, 2008.
103. E. M. Hennes, M. Zeniya, A. J. Czaja, A. Parés, **G. N. Dalekos**, E. Krawitt, P.L. Bittencourt, G. Porta, K.M. Boberg, H. Hofer, F.B. Bianchi, M. Shibata, C. Schramm, B. Eisenmann de Torres, P. R. Galle, I. McFarlane, H. P. Dienes, A. W. Lohse. Simplified criteria for the diagnosis of autoimmune hepatitis. *Hepatology* 48:169-176, 2008.
104. Y. Renaudineau, **G.N. Dalekos**, P. Guéguen, K. Zachou, P. Youinou. Anti- α -actinin antibodies cross-react with anti-ssDNA antibodies in active autoimmune hepatitis. *Clin Rev Allergy Immunol* 34:321-325, 2008.
105. **G.N. Dalekos**, D.P. Bogdanos and J. Neuberger. Celiac disease-related autoantibodies in end-stage autoimmune liver diseases: What is the message? *Liver Int* 28:426-428, 2008. **(Editorial)**.
106. K. Zachou, P. Papamichalis, **and G.N. Dalekos**. Severe pharyngitis in stockbreeders: an unusual presentation of brucellosis. *Occup Med* 58:305-307, 2008.
107. E.I. Rigopoulou **and G.N. Dalekos**. Molecular diagnostics of primary biliary cirrhosis. *Expert Opin Med Diagn (now Expert Rev Mol Diagn)* 2: 621-634, 2008. **(Invited review)**.
108. D.P. Bogdanos **and G.N. Dalekos**. Enzymes as autoantigens of liver-specific autoimmunity. *Curr Med Chem* 15:2285-2292, 2008. **(Invited review)**.
109. A. Tsirikoni, E.I. Rigopoulou, K. Zachou, C. Liaskos, D. Kyriakou, **and GN Dalekos**. Bone marrow findings in patients with autoimmune liver diseases. *J Gastroenterol Hepatol* 23: e416-21, 2008.
110. K. Kyriakopoulou, A. Antoniou, I.V. Fezoulidis, N.L. Kelekis, **G.N. Dalekos**, M. Vlychou. The role of Doppler Perfusion Index as screening test in the characterization of focal liver lesions. *Digest Liver Dis* 40: 755-60, 2008.
111. N.K. Gatselis, S. Barbanis, F. Karasavidou, **G.N. Dalekos**. Could 90's be a second childhood period? The case of Henoch-Schonlein purpura. *Age & Ageing* 37: 483, 2008.
112. P. Fytily, **G.N. Dalekos**, M. Cornberg, V. Schlaphoff, W. Zauner, K. Zachou, M.P. Manns, C. Klade and H. Wedemeyer. Cross-genotype-reactivity of the immunodominant HCV-CD8 T-cell epitope NS3-1073: Significance for the development of peptide-based vaccines against HCV. *Vaccine* 26: 3818-26, 2008.
113. Stefanidis I, Giannopoulou M, Liakopoulos V, Dovas S, Karasavidou F, Zachou K, Koukoulis GK, **Dalekos GN**. A case of membranous nephropathy associated with Sjogren syndrome, polymyositis and autoimmune hepatitis. *Clin Nephrol* 70: 245-50, 2008.
114. S. Gabeta, G.L. Norman, C. Liaskos, N. Gatselis, P.A. Papamichalis, A. Garagounis, K. Zachou, E.I. Rigopoulou **and G.N. Dalekos**. IgA anti-b2GPI antibodies in patients with autoimmune liver diseases. *J Clin Immunol* 28: 501-11, 2008.
115. I. Goulis **and G.N. Dalekos**. Entecavir monotherapy for lamivudine-refractory chronic hepatitis B. *Expert Rev Anti-Infect Ther* 6:855-859, 2008. **(Invited review)**.
116. A. Stefos, N. Gatselis, K. Zachou, E. Rigopoulou, C. Hadjichristodoulou, **and G.N. Dalekos**. Descriptive epidemiology of chronic hepatitis B by using data from a hepatitis registry in central Greece. *Eur J Intern Med* 20: 35-43, 2009.

- 117.S.P. Georgiadou, C. Liaskos, K. Zachou, S. Gabeta, E.I. Rigopoulou, **and G.N. Dalekos**. Occult hepatitis B virus infection in Greek patients with autoimmune liver diseases. *Liver Int* 29: 434-42, 2009.
- 118.Makaritsis KP, Gatselis NK, Ioannou M, Petinaki E, **Dalekos GN**. Polyclonal hypergammaglobulinaemia and high smooth muscle autoantibodies titres with specificity against filamentous actin: Consider visceral leishmaniasis, not just autoimmune hepatitis. *Int J Infect Dis* 13: e157-60, 2009.
- 119.S.P. Georgiadou **and G.N. Dalekos**. Which level of immunosuppression is harmful for occult hepatitis B virus infection? 'A million dollar's answer. *Liver Int* 29: 1127-1128, 2009.
- 120.KP Makaritsis, Ch Neocleous, N Gatselis, E Petinaki **and GN Dalekos**. An immunocompetent patient presenting with severe septic arthritis due to *Ralstonia pickettii* identified by molecular-based assays: a case report. *Cases J* 2: 8125, 2009.
- 121.E. Kapsalaki, N. Gatselis, A. Stefos, K. Makaritsis, A. Vassiou, I. Fezoulidis, **G.N. Dalekos**. Spontaneous spondylodiscitis: Presentation, risk factors, diagnosis, management and outcome *Int J Infect Dis* 13: 564-569, 2009.
- 122.A. Koutsoumpas, M. Mytilinaiou, D. Polymeros, **G.N. Dalekos**, D.P. Bogdanos. Anti-*Helicobacter pylori* antibody responses specific for VacA do not trigger primary biliary cirrhosis-specific anti-mitochondrial antibodies. *Eur J Gastroenterol Hepatol (letter)* 21: 1220, 2009.
- 123.E. Tsironi, N. Gatselis, M.G. Kotoula, K. Zachou, M. Pefkianaki, F. Zacharaki, D.Z. Chatzoulis **and G.N. Dalekos**. Ocular disorders as the prevailing manifestations of the antiphospholipid syndrome: three case reports. *Cases J* 2:159, 2009.
- 124.K. Zachou, C. Yurdaydin, U. Drebber, **G.N. Dalekos**, A. Erhardt, Y Cakaloglu, H. Degertekin, S. Gurel, S. Zeuzem, H. Bozkaya, V. Schlaphoff, H.P. Dienes, C.T. Bock, M.P. Manns and H. Wedemeyer for HDT-1 Study Group. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. *Liver Int* 30:430-437, 2010.
- 125.P. Mina, S.P. Georgiadou, C. Rizos, **G.N. Dalekos**, E.I. Rigopoulou. Prevalence of occult HBV infection in haemodialysis patients from central Greece. *World J Gastroenterol* 16:225-31, 2010.
- 126.Liaskos C, Norman GL, Moulas A, Garagounis A, Goulis I, Rigopoulou EI, **Dalekos GN**. Prevalence of gastric parietal cell antibodies and intrinsic factor antibodies in primary biliary cirrhosis. *Clin Chim Acta* 411:411-5, 2010.
- 127.E.I. Rigopoulou, **G.N. Dalekos**. Can mathematical models be useful in clinical hepatology? *Liver Int* 30:637-638, 2010. (Editorial).
- 128.Gatselis NK, Zachou K, **Dalekos GN**. Early primary biliary cirrhosis: a new association with erythema nodosum of unknown origin. *Gastroenterol Res Pract* 2010. pii: 121620, 2010.
- 129.Gatselis NK, Zachou K, Papamichalis P, Koukoulis GK, Gabeta S, **Dalekos GN**, Rigopoulou EI. Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: A new or a complementary diagnostic score? *Digest Liver Dis* 42:807-812, 2010.
- 130.Liu H, Norman GL, Shums Z, Worman HJ, Krawitt EL, Bizzaro N, Vergani D, Bogdanos DP, **Dalekos GN**, Milkiewicz P, Czaja AJ, Heathcote JE, Hirschfield GM, Tan EM, Miyachi K, Bignotto M, Battezzati P-M, Lleo A, Leung PS, Podda M, Gershwin ME, Invernizzi P. PBC Screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. *J Autoimmun* 35:436-442, 2010.

131. Gatselis NK and **Dalekos GN**. Education and imaging. Hepatobiliary and pancreatic: Primary hepatic lymphoma. *J Gastroenterol Hepatol* 26:210, 2011.
132. Gatselis NK, Makaritsis KP, Gabranis I, Karanikas K and **Dalekos GN**. Unusual cardiovascular complications of brucellosis presenting in two men: two case reports and a review of the literature. *J Med Case Reports* 5:22, 2011.
133. Wedemeyer H, Yurdaydin C, **Dalekos GN**, Erhardt A, Çakaloğlu Y, Değertekin H, Gürel S, Zeuzem S, Zachou K, Bozkaya H, Koch A, Bock T, Dienes HP, Manns MP. Peginterferon plus adefovir versus either drug alone for hepatitis delta. *New Engl J Med* 364:322-331, 2011.
134. Zachou K, **Dalekos GN**. Hepatitis B re-activation with rituximab therapy: treat the patient not the disease. *Liver Int* 31:277-279, 2011. (Editorial).
135. Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, **Dalekos GN**. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. *J Hepatol* 55:636-646, 2011.
136. Oikonomou KG, Zachou K, **Dalekos GN**. Alpha-actinin: a multidisciplinary protein with important role in B-cell driven autoimmunity. *Autoimmun Rev* 10:389-396, 2011.
137. Papamichalis P, Argyraki K, Papamichalis M, Loukopoulos A, **Dalekos GN**, Rigopoulou EI. Salmonella enteritidis infection complicated by acute myocarditis: a case report and review of the literature. *Cardiol Res Pract* 2011:574230, 2011.
138. Koumati E, Palassopoulou M, Matsouka P, Polyzos A, **Dalekos GN**, Zachou K. Multiple autoimmune propensity and B-non-hodgkin lymphoma: cause or effect? *Autoimmune Dis* 2011:841325, 2011.
139. Argyraki CK, Gabeta S, Zachou K, Boulbou M, Polyzos A, **Dalekos GN**. Favourable outcome of life-threatening infectious-related haemophagocytic syndrome after combination treatment with corticosteroids and intravenous immunoglobulin infusions. *Eur J Intern Med* 22:155-157, 2011.
140. Papamichalis P, Alexiou A, Boulbou M, **Dalekos GN**, Rigopoulou EI. Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy? *Clin Res Hepatol Gastroenterol (previous Gastroentérologie Clinique et Biologique)* 36:84-93, 2012.
141. Mederacke I, Yurdaydin C, **Dalekos GN**, Bremer B, Erhardt A, Cakaloglu Y, Yalcin K, Gurel S, Zeuzem S, Zachou K, Bozkaya H, Dienes HP, Manns MP, Wedemeyer H, Hep-Net/International Delta Hepatitis Study Group. Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon- α 2a treatment. *Antivir Ther* 17:305-312, 2012.
142. Tillmann HL, Zachou K, **Dalekos GN**. Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat? *Liver Int* 32:544-553, 2012.
143. Mavroidi A, Miriagou V, Malli E, Stefos A, **Dalekos GN**, Tzouvelekis LS, Petinaki E. Emergence of Escherichia coli sequence type 410 (ST410) with KPC-2 β -lactamase. *Int J Antimicrob Agents* 39:247-250, 2012.
144. Zachou K, Oikonomou K, Renaudineau Y, Chauveau A, Gatselis N, Youinou P, **Dalekos GN**. Anti- α actinin antibodies as new predictors of response to treatment in autoimmune hepatitis type 1. *Aliment Pharmacol Ther* 35:116-125, 2012.
145. Mederacke I, Yurdaydin C, Großhennig A, Erhardt A, Cakaloglu Y, Yalcin K, Gurel S, Zeuzem S, Zachou K, Chatzikyrkou C, Bozkaya H, **Dalekos GN**, Manns MP, Wedemeyer H; on behalf of Hep-Net/International Delta Hepatitis Study Group. Renal function during

treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection. *J Viral Hepat* 19:387-395, 2012.

146. Gatselis NK, Liamis G, Makaritsis KP, **Dalekos GN**. Metabolic acidosis during treatment of mushroom poisoning: a diagnostic pitfall. *Intern Med* 51:1077-1080, 2012.
147. Gatselis NK, Zachou K, Norman GL, Tzellas G, Speletas M, Gabeta S, Germenis A, Koukoulis GK, **Dalekos GN**. IgA antibodies against deamidated gliadin peptides in patients with chronic liver diseases. *Clin Chim Acta* 413:1683-1688, 2012.
148. Stefos A, Gatselis N, Goudelas A, Mpakarosi M, Papaparaskevas J, **Dalekos G**, Petinaki E. Cutaneous infection caused by *Bacillus anthracis* in Larissa, Thessaly, Central Greece, July 2012. *Euro Surveill* 17(32). pii: 20245, 2012.
149. Zografos TA, Gatselis N, Zachou K, Liaskos C, Gabeta S, Koukoulis GK, **Dalekos GN**. PBC-specific autoantibodies in first degree relatives of Greek PBC patients. *World J Gastroenterol* 18:4721-4728, 2012.
150. Kabaçam G, **Dalekos GN**, Cakaloğlu Y, Zachou K, Bock T, Erhardt A, Zeuzem S, Tabak F, Yalçın K, Bozdayi AM, Dienes HP, Bozkaya H, Manns M, Wedemeyer H, Yurdaydin C. Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. *Turk J Gastroenterol* 23:560-568, 2012.
151. Skrimpas S, Polyzos A, **Dalekos GN**, Zachou K. Quiz: Sternoclavicular joint swelling in a previously healthy adult. *Internal Med: Open Access* 2:2, 2012.
152. Saitis A, Gatselis NK, **Dalekos GN**. Leishmaniasis-associated haemophagocytic syndrome revisited: not an uncommon clinical presentation of leishmaniasis. *J Med Cases* 3:315-318, 2012.
153. Mavroidi A, Miriagou V, Liakopoulos A, Tzelepi E, Stefos A, **Dalekos GN**, Petinaki E. Ciprofloxacin-resistant *Escherichia coli* in Central Greece: mechanisms of resistance and molecular identification. *BMC Infect Dis* 12:371, 2012.
154. Zellos A, Spoulou V, Roma-Giannikou E, Karentzou O, **Dalekos GN**, Theodoridou M. Autoimmune hepatitis type-2 and Epstein-Barr virus infection in a toddler: art of facts or an artifact? *Ann Hepatol* 12:147-151, 2013.
155. Ntaios G, Gatselis NK, Makaritsis K, **Dalekos GN**. Adipokines as mediators of endothelial function and atherosclerosis. *Atherosclerosis* 227:216-221, 2013.
156. J.Z. Liu, J.R. Hov, T. Folseraas, E. Ellinghaus, S.M. Rushbrook, N.T. Doncheva, O.A. Andreassen, R.K. Weersma, T.J. Weismüller, B. Eksteen, P. Invernizzi, G.M. Hirschfield, D.N. Gotthardt, A. Pares, D. Ellinghaus, T. Shah, B.D. Juran, P. Milkiewicz, C. Rust, C. Schramm, T. Müller, B. Srivastava, **G. Dalekos**, M.M. Nöthen, J. Winkelmann, M. Mitrovic, F. Braun, C.Y. Ponsioen, P.J.P. Croucher, M. Sterneck, A. Teufel, A.L. Mason, J. Saarela, V. Leppa, V. Pelkonen, R. Dorfman, D. Alvaro, A. Floreani, S. Onengut-Gumuscu, S.S. Rich, W.K. Thompson, A.J. Schork, S. Næss, I. Thomsen, G. Mayr, I.R. König, K. Hveem, I. Cleynen, J. Gutierrez-Achury, I. Ricaño-Ponce, D. van Heel, E. Björnsson, R.N. Sandford, P.R. Durie, E. Melum, M.H. Vatn, M. Silverberg, R.H. Duerr, L. Padyukov, S. Brand, M. Sans, V. Annese, Jean-Paul Achkar, K.M. Boberg, H-U Marschall, O. Chazouillères, C.L. Bowlus, C. Wijmenga, E. Schrupf, S. Vermeire, M. Albrecht, The UK-PSC Consortium, The International IBD Genetics Consortium, J.D. Rioux, G. Alexander, A. Bergquist, J. Cho, S. Schreiber, M.P. Manns, M. Färkkilä, A.M. Dale, R.W. Chapman, K.N. Lazaridis, The International PSC Study Group, A. Franke, C.A. Anderson, T.H. Karlsen. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. *Nature Genetics* 45:670-675, 2013.

157. A Mazioti, NK Gatselis, C Rountas, K Zachou, DK Filippiadis, K Tepetes, GK Koukoulis, I Fezoulidis, **GN Dalekos**. Safety and efficacy of transcatheter arterial chemoembolization in the real-life management of unresectable hepatocellular carcinoma. *Hepat Mon* 13:e7070, 2013.
158. Saitis A, Gatselis N, Zachou K, **Dalekos GN**. Use of TNF α antagonists in refractory AIH: revealing the unforeseen. *J Hepatol (Letter)* 59:197-198, 2013.
159. Gatselis NK, Zachou K, Norman GL, Gabeta S, Papamichalis P, Koukoulis GK, **Dalekos GN**. Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. *Autoimmunity* 46:471-479, 2013.
160. Zachou K, Sarantopoulos A, Gatselis NK, Vassiliadis T, Gabeta S, Stefos A, Saitis A, Boura P, **Dalekos GN**. HBV reactivation in HBsAg negative patients receiving immunosuppression: a hidden threat. *World J Hepatol* 5:387-392, 2013.
161. Manesis EK, Vourli G, **Dalekos G**, Vasiliadis T, Manolaki N, Hounta A, Koutsounas S, Vafiadis I, Nikolopoulou G, Giannoulis G, Germanidis G, Papatheodoridis G, Touloumi G. Prevalence and clinical course of hepatitis delta infection in Greece: A 13-year prospective study. *J Hepatol* 59:949-956, 2013.
162. Zachou K, Muratori P, Koukoulis GK, Granito A, Gatselis N, Fabbri A, **Dalekos GN**, Muratori L. Review article: Autoimmune hepatitis – current management and challenges. *Aliment Pharmacol Ther* 38:887-913, 2013.
163. Rigopoulou EI, Zachou K, Gatselis NK, Papadamou G, Koukoulis GK, **Dalekos GN**. Primary biliary cirrhosis in HBV and HCV patients: Clinical characteristics and outcome. *World J Hepatol* 5:577-583, 2013.
164. Rigopoulou EI, Zachou K, Gatselis N, Koukoulis GK, **Dalekos GN**. Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome. *Ann Hepatol* 13:127-135, 2014.
165. Gatselis NK, Ntaios G, Makaritsis K, **Dalekos GN**. Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease. *Clin Exp Med* 14:121-31, 2014.
166. Georgiadou SP, Velegaki A, Arabatzis M, Neonakis I, Chatzipanagiotou S, **Dalekos GN**, Petinaki E. Cluster of *Fusarium verticillioides* bloodstream infections among immunocompetent patients in an internal medicine department after reconstruction works in Larissa, Central Greece. *J Hosp Infect* 86:267-71, 2014.
167. Gatselis NK, Zachou K, Saitis A, Samara M, **Dalekos GN**. Individualization of chronic hepatitis C treatment according to the host characteristics. *World J Gastroenterol* 20:2839-2853, 2014 (**Invited review**).
168. Anagnostou O, Manolakopoulos S, Bakoyannis G, Papatheodoridis G, Zisouli A, Raptopoulou-Gigi M, Manesis E, Ketikoglou I, **Dalekos G**, Gogos C, Vassiliadis T, Tzourmakliotis D, Karatapanis S, Kanatakis S, Zoumpoulis-Vafiadis I, Hounta A, Koutsounas S, Giannoulis G, Tassopoulos N, Touloumi G. Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study. *Hippokratia* 18:57-64, 2014.
169. Kabaçam G, Wedemeyer H, Savaş B, Keskin O, **Dalekos G**, Tabak F, Idilman R, Erhardt A, Yalçın K, Bozdayi MA, Bozkaya H, Manns M, Dienes H, Yurdaydın C; the HIDIT-1 Study Group. Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta. *Liver Int* 34:1207-1215, 2014.
170. Heidrich B, Yurdaydın C, Kabaçam G, Ratsch BA, Zachou K, Bremer B, **Dalekos GN**, Erhardt A, Tabak F, Yalçın K, Gurel S, Zeuzem S, Cornberg M, Bock CT, Manns MP, Wedemeyer H.

Late HDV RNA relapse after peginterferon alfa-based therapy of chronic hepatitis delta. *Hepatology* 60:87-97, 2014.

171. Wiegand J, Wedemeyer H, Franke A, Rößler S, Zeuzem S, Teuber G, Wächter M, Römmele U, Ruf B, Spengler U, Trautwein C, Bock CT, Fiedler GM, Thiery J, Manns MP, Brosteanu O, Tillmann HL; **German Hep-Net Acute Hepatitis B (GAHB) Study Group**. Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trial. *J Viral Hepat* 21:744-750, 2014.
172. Kaffe ET, Rigopoulou EI, Koukoulis GK, **Dalekos GN**, Moulas AN. Oxidative stress and antioxidant status in patients with autoimmune liver diseases. *Redox Rep* 20:33-41, 2015.
173. Gatselis N, Zachou K, Koukoulis GK, **Dalekos GN**. Autoimmune hepatitis, one disease with many faces: Etiopathogenetic, clinico-laboratory and histological characteristics. *World J Gastroenterol* 21: 60-83, 2015. **(Invited review)**.
174. Papatheodoridis GV, **Dalekos GN**, Yurdaydin C, Buti M, Goulis J, Arends P, Sypsa V, Manolakopoulos S, Mangia G, Gatselis N, Keskin O, Savvidou S, Hansen BE, Papaioannou C, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. *J Hepatol* 62:363-370, 2015.
175. Zachou K, Gampeta S, Gatselis NK, Oikonomou K, Goulis J, Manoussakis MN, Renaudineau Y, Bogdanos DP, **Dalekos GN**. Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis. *Liver Int* 35:660-672, 2015.
176. Papatheodoridis GV, Manolakopoulos S, Touloumi G, Nikolopoulou G, Raptopoulou-Gigi M, Gogos C, Vafiadis-Zouboulis I, Karamanolis D, Chouta A, Ilias A, Drakoulis C, Mimidis K, Ketikoglou I, Manesis E, Mela M, Hatzis G, **Dalekos GN**. Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort. *J Viral Hepat* 22:118-125, 2015.
177. Georgiadou SP, Makaritsis KP, **Dalekos GN**. Leishmaniasis revisited: Current aspects on epidemiology, diagnosis and treatment. *J Transl Int Med* 3:43-50, 2015. **(Invited review)**.
178. Ntaios G, Melikoki V, Perifanos G, Perlepe K, Gioulekas F, Karagiannaki A, Tsantzali I, Lazarou C, Beradze N, Poulianiti E, Poulidakou M, Palantzas F, Kaditi S, Perlepe F, Sidiropoulos G, Papageorgiou K, Papavasileiou V, Vemmos K, Makaritsis K, **Dalekos GN**. Poor stroke risk perception despite moderate public stroke awareness: insight from a cross-sectional national survey in Greece. *J Stroke Cerebrovasc Dis* 24:721-724, 2015.
179. Goulis I, Karatapanis S, Akriadiadis E, Deutsch M, **Dalekos GN**, Raptopoulou-Gigi M, Mimidis K, Germanidis G, Drakoulis C, Triantos C, Zintzaras E, Bakalos G, Papatheodoridis G. On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients. *Liver Int* 35:1540-1548, 2015.
180. Georgiadou SP, Stefos A, Spanakos G, Skrimpas S, Makaritsis K, Sipsas NV, **Dalekos GN**. Current clinical, laboratory and treatment outcome characteristics of visceral leishmaniasis: results from a 7-year retrospective study in Greece. *Int J Infect Dis* 34:e46-e50, 2015.
181. Sarrou S, Liakopoulos A, Chasioti M, Billinis C, Foka A, Tzanetou K, Pantelidi K, Roussaki-Schulze A, Hadjihannas L, Lachanas V, Skoulakis C, Makaritsis K, Daikos GL, **Dalekos G**, Spiliopoulou I, Petinaki E. Dissemination of methicillin-susceptible CC398 *Staphylococcus aureus* strains in a rural Greek area. *PLoS One* 10:e0122761, 2015.
182. Kalafateli M, Kourakli A, Gatselis NK, Lambropoulou P, Thomopoulos K, Tsamandas A, Christofidou M, Zachou K, Jelastopoulou E, Nikolopoulou V, Symeonidis A, **Dalekos GN**,

- Lambropoulou-Karatza C, Triantos CK. Efficacy of interferon a-2b monotherapy in b-thalassemics with chronic hepatitis C. *J Gastrointestin Liver Dis* 24:189-196, 2015.
183. Makaritsis KP, Liaskos C, Papadamou G, **Dalekos GN**. Spontaneous bacterial peritonitis: an unusual manifestation of brucellosis in a previous healthy male patient. *BMJ Case Reports pii: bcr2015209387*, 2015.
184. Keskin O, Wedemeyer H, Tüzün A, Zachou K, Deda X, **Dalekos GN**, Heidrich B, Pehlivan S, Zeuzem S, Yalçın K, Gürel S, Tabak F, Idilman R, Bozkaya H, Manns M, Yurdaydin C. Association between level of hepatitis D virus RNA at week 24 of pegylated interferon therapy and outcome. *Clin Gastroenterol Hepatol* 13:2342-2349, 2015.
185. Norman GL, Gatselis NK, Shums Z, Liaskos C, Bogdanos DP, Koukoulis GK, **Dalekos GN**. Cartilage oligomeric matrix protein: A novel non-invasive marker for assessing cirrhosis and risk of hepatocellular carcinoma. *World J Hepatol* 7:1875-1883, 2015.
186. Lyberopoulou A, Chachami G, Gatselis NK, Kyrtzopoulou E, Saitis A, Gabeta S, Eliades P, Paraskeva E, Zachou K, Koukoulis GK, Mamalaki A, **Dalekos GN**, Simos G. Low serum hepcidin in patients with autoimmune liver diseases. *PLoS One* 10:e0135486, 2015.
187. **European Association for the Study of the Liver***. EASL Clinical Practice Guidelines: Autoimmune hepatitis. *J Hepatol* 63:971-1004, 2015. *Chairman: Ansgar W. Lohse. Panel members: Olivier Chazouilleres, **George Dalekos**, Joost Drenth, Michael Heneghan, Harald Hofer, Frank Lammert, Marco Lenzi.
188. Seaton RA, Menichetti F, **Dalekos G**, Beiras-Fernandez A, Nacinovich F, Pathan R, Hamed K. Evaluation of effectiveness and safety of high-dose daptomycin: Results from patients included in the European Cubicin(®) Outcomes Registry and Experience. *Adv Ther* 32:1192-1205, 2015.
189. Oikonomou O, Sarrou S, Papagiannitsis CC, Georgiadou S, Mantzaris K, Zakyntinos E, **Dalekos GN**, Petinaki E. Rapid dissemination of colistin and carbapenem resistant *Acinetobacter baumannii* in Central Greece: mechanisms of resistance, molecular identification and epidemiological data. *BMC Infect Dis* 15:559, 2015.
190. Papatheodoridis G, **Dalekos G**, Sypsa V, Yurdaydin C, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Mangia G, Gatselis N, Keskin O, Savvidou S, de la Revilla J, Hansen BE, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. Page-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. *J Hepatol* 64:800-806, 2016.
191. Papatheodoridis G, Thomas HC, Golna C, Bernardi M, Carballo M, Cornberg M, **Dalekos G**, Degertekin B, Dourakis S, Flisiak R, Goldberg D, Gore C, Goulis I, Hadziyannis S, Kalamitsis G, Kanavos P, Kautz A, Koskinas I, Leite BR, Malliori M, Manolakopoulos S, Matičić M, Papaevangelou V, Pirona A, Prati D, Raptopoulou-Gigi M, Reic T, Robaeys G, Schatz E, Souliotis K, Tountas Y, Wiktor S, Wilson D, Yfantopoulos J, Hatzakis A. Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference. *J Viral Hepat* 23(Suppl 1):1-12, 2016.
192. Zachou K, Gatselis NK, Arvaniti P, Gabeta S, Rigopoulou EI, Koukoulis GK, **Dalekos GN**. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis. *Aliment Pharmacol Ther* 43:1035-1047, 2016. **(Original article with Editorial)**.
193. Lohse AW, Chazouilleres O, **Dalekos G**, Drenth JP, Heneghan M, Hofer H, Lammert F, Lenzi M; EASL Clinical Practice Guidelines: Autoimmune hepatitis panel. Reply to "Further considerations in autoimmune hepatitis". *J Hepatol* 64:1458-1459, 2016.

194. **Dalekos GN**, Zachou K. Editorial: autoimmune hepatitis - identifying options for treatment. Authors' reply. *Aliment Pharmacol Ther* 43:1237-1238, 2016.
195. Kalafateli M, Triantos C, Tsamandas A, **Dalekos GN**. Spontaneous cirrhosis regression in an IFN-beta-induced AIH-like syndrome following drug withdrawal: Art of facts or artifacts? *Eur J Case Rep Intern Med* 3:doi:10.12890/2016_000396, 2016.
196. Gatselis NK, **Dalekos GN**. Molecular diagnostic testing for primary biliary cholangitis. *Expert Rev Mol Diagn* 16:1001-1010, 2016. (Invited review).
197. Gatselis NK, Skendros P, Ritis K, **Dalekos GN**. Severe liver involvement in two patients with long-term history of fever: remember familial Mediterranean fever. *BMJ Case Rep pii: bcr2016216941*, 2016.
198. Vourli G, Papatheodoridis G, Raptopoulou M, **Dalekos GN**, Hounta A, Nikolopoulou G, Zouboulis-Vafeiadis I, Manesis E, Kitis G, Gogos C, Ketikoglou I, Hatzis G, Vasiliadis T, Karatapanis S, Mimidis K, Drakoulis C, Touloumi G, The Hep-net-Greece. Association of antiviral therapy with reduced disease progression in chronic hepatitis B patients: Results from a nation-wide cohort study. *Hippokratia* 20:214-221, 2016.
199. Zachou K, Arvaniti P, Gatselis NK, Azariadi K, Papadamou G, Rigopoulou E, **Dalekos GN**. Patients with haemoglobinopathies and chronic hepatitis C: A real difficult to treat population in 2016? *Medit J Hematol Infect Dis* 9:e2017003, 2017.
200. Giamarellos-Bourboulis EJ, Tsaganos T, Tsangaris I, Lada M, Routsis C, Sinapidis D, Koupetori M, Bristianou M, Adamis G, Mandragos K, **Dalekos GN**, Kritselis I, Giannikopoulos G, Koutelidakis I, Pavlaki M, Antoniadou E, Vlachogiannis G, Koulouras V, Prekates A, Dimopoulos G, Koutsoukou A, Pnevmatikos I, Ioakeimidou A, Kotanidou A, Orfanos SE, Armaganidis A, Gogos C; Hellenic Sepsis Study Group. Validation of the new sepsis-3 definitions: proposal for improvement in early risk identification. *Clin Microbiol Infect* 23:104-109, 2017.
201. Mangia A, Foster GR, Berg CP, Curescu M, De Ledinghen V, Habersetzer F, Manolakopoulos S, Negri E, Papatheodoridis G, Ahlers S, Castillo M, Bakalos G, Mauss S on behalf of **the PegBase Group Investigators**. Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study. *Ann Gastroenterol* 30:327-343, 2017.
202. Zachou K, Gabeta S, Shums Z, Gatselis NK, Koukoulis GK, Norman GL, **Dalekos GN**. COMP serum levels: A new non-invasive biomarker of liver fibrosis in patients with chronic viral hepatitis. *Eur J Intern Med* 38:83-88, 2017.
203. Laskari K, Boura P, **Dalekos GN**, Garyfallos A, Karokis D, Pikazis D, Settas L, Skarantavos G, Tsitsami E, Sfikakis PP. Long-term beneficial effect of Canakinumab in colchicine-resistant Familial Mediterranean fever. *J Rheumatol* 44:102-109, 2017.
204. Gutiérrez-Gutiérrez B, Sojo-Dorado J, Bravo-Ferrer J, Cuperus N, de Kraker M, Kostyanov T, Raka L, Daikos G, Feifel J, Folgiori L, Pascual A, Goossens H, O'Brien S, Bonten MJ, Rodríguez-Baño J; **EURECA project team**. European prospective cohort study on Enterobacteriaceae showing REsistance to CARbapenems (EURECA): a protocol of a European multicentre observational study. *BMJ Open* 7:e015365, 2017.
205. Liberal R, de Boer YS, Andrade RJ, Bouma G, **Dalekos GN**, Floreani A, Gleeson D, Hirschfield G, Invernizzi P, Lenzi M, Lohse A, Macedo G, Milkiewicz P, Terziroli B, van Hoek B, Vierling J, Heneghan MA, on behalf of the International Autoimmune Hepatitis Group (IAIHG). Expert clinical management of autoimmune hepatitis in the real world. *Aliment Pharmacol Ther* 45:723-732, 2017.

206. Kaffe E, Katsifa A, Xylourgidis N, Ninou I, Zannikou M, Moissidou D, Foka P, Dimitriadis A, Georgopoulou U, Gorgoulis VG, **Dalekos GN** and Aidinis V. Hepatocyte autotaxin expression promotes liver fibrosis and cancer. *Hepatology* 65:1369-1383, 2017.
207. Gatselis NK, Vakrakou AG, Zachou K, Androutsakos T, Azariadi K, Hatzis G, Manoussakis MN, **Dalekos GN**. Decreased serum DNase1-activity in patients with autoimmune liver diseases. *Autoimmunity* 50:125-132, 2017.
208. Weismüller TJ, Trivedi PJ, Bergquist A, Imam M, Lenzen H, Ponsioen CY, Holm K, Gotthardt D, Färkkilä MA, Marschall HU, Thorburn D, Weersma RK, Fevery J, Mueller T, Chazouillères O, Schulze K, Lazaridis KN, Almer S, Pereira SP, Levy C, Mason A, Naess S, Bowlus CL, Floreani A, Halilbasic E, Yimam KK, Milkiewicz P, Beuers U, Huynh DK, Pares A, Manser CN, **Dalekos GN**, Eksteen B, Invernizzi P, Berg CP, Kirchner GI, Sarrazin C, Zimmer V, Fabris L, Braun F, Marzioni M, Juran BD, Said K, Rupp C, Jokelainen K, Benito de Valle M, Saffioti F, Cheung A, Trauner M, Schramm C, Chapman RW, Karlsen TH, Schrupf E, Strassburg CP, Manns MP, Lindor KD, Hirschfield GM, Hansen BE, Boberg KM; International PSC Study Group. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. *Gastroenterology* 152:1975-1984, 2017.
209. Rigopoulou EI, Ioannou M, Papadamou G, **Dalekos GN**. Ascites in a patient with episodic angio-oedema and eosinophilia: thinking outside the box. *BMJ Case Rep pii: bcr-2017-219467*, 2017.
210. Sinakos E, Kountouras D, Koskinas J, Zachou K, Karatapanis S, Triantos Ch, Vassiliadis Th, Goulis I, Kourakli A, Vlachaki E, Toli B, Tampaki M, Arvaniti P, Tsiaoussis G, Bellou A, Kattamis A, Maragkos K, Petropoulou F, **Dalekos GN**, Akriviadis E, Papatheodoridis GV. Treatment of advanced chronic hepatitis C with direct-acting antivirals in patients with β -thalassemia major results in high response rates with excellent safety. *Br J Haematol* 178:130-136, 2017.
211. Gatselis NK, Zachou K, Lygoura V, Azariadis K, Arvaniti P, Spyrou E, Papadamou G, Koukoulis GK, **Dalekos GN**, Rigopoulou EI. Geoepidemiology, clinical manifestations and outcome of primary biliary cholangitis in Greece. *Eur J Intern Med* 42:81-88, 2017.
212. Zachou K, Gabeta S, Gatselis NK, Norman GL, **Dalekos GN**. Cartilage oligomeric matrix protein on the spot for liver fibrosis evaluation: Too early or too late? *Eur J Intern Med* 43:e48-e49, 2017.
213. Papatheodoridis GV, Idilman R, **Dalekos GN**, Buti M, Chi H, van Boemmel F, Calleja JL, Sypsa V, Goulis J, Manolakopoulos S, Loglio A, Siakavelas S, Keskin O, Gatselis N, Hansen BE, Lehretz M, de la Revilla J, Savvidou S, Kourikou A, Vlachogiannakos I, Galanis K, Yurdaydin C, Berg T, Colombo M, Esteban R, Janssen HLA, Lampertico P. The risk of hepatocellular carcinoma is decreasing after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. *Hepatology* 66:1444-1463, 2017.
214. Skoutelis A, Pefanis A, Tsiodras S, Sipsas NV, Lelekis M, Lazanas MC, Gargalianos P, **Dalekos GN**, Roilides E, Samonis G, Maltezos E, Hatzigeorgiou D, Lada M, Metallidis S, Stoupis A, Chrysos G, Karnesis L, Symbardi S, Loupa CV, Giamarellou H, Kioumis I, Sambatakou H, Tsianos E, Kotsopoulou M, Georgopali A, Liakou K, Perlorentzou S, Levidiotou S, Giotsa-Toutouza M, Tsorlini-Christoforidou H, Karaiskos I, Kouppari G, Trikka-Graphakos E, Ntrivala MA, Themeli-Digalaki K, Pangalis A, Kachrimanidou M, Martsoukou M, Karapsias S, Panopoulou M, Maraki S, Orfanou A, Petinaki E, Orfanidou M, Baka V, Stylianakis A, Spiliopoulou I, Smilakou S, Zerva L, Vogiatzakis E, Belesiotou E, Gogos CA. Point-prevalence survey of healthcare facility-onset healthcare-associated *Clostridium difficile* infection in Greek hospitals outside the intensive care unit: The C. DEFINE study. *PLoS One* 12:e0182799, 2017.

215. Papatheodoridi M, **Dalekos GN**, Goulis J, Manolakopoulos S, Triantos C, Zachou K, Koukoulou A, Kourikou A, Zisimopoulos K, Tsoulas C, Papatheodoridis GV. Prioritization for interferon-free regimens and potential drug interactions of current direct-acting anti-hepatitis C agents in routine clinical practice. *Ann Gastroenterol* 30:542-549, 2017.
216. Polychronopoulou E, Lygoura V, Gatselis NK, **Dalekos GN**. Increased cholestatic enzymes in two patients with long-term history of ulcerative colitis: consider primary biliary cholangitis not always primary sclerosing cholangitis. *BMJ Case Rep pii: bcr-2017-220824*, 2017.
217. Doumstis P, Oikonomou T, Goulis I, Zachou K, **Dalekos G**, Cholongitas E. Type 1 autoimmune hepatitis presenting with severe autoimmune neutropenia. *Ann Gastroenterol* 31:123-126, 2018.
218. Harms MH, Lammers WJ, Thorburn D, Corpechot C, Invernizzi P, Janssen HLA, Battezzati PM, Nevens F, Lindor KD, Floreani A, Ponsioen CY, Mayo MJ, **Dalekos GN**, Bruns T, Parés A, Mason AL, Verhelst X, Kowdley KV, Goet JC, Hirschfield GM, Hansen BE, van Buuren HR. Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis: Risk factors and time trends in incidence and outcome. *Am J Gastroenterol* 113:254-264, 2018.
219. Arvaniti P, Zachou K, Koukoulis GK, **Dalekos GN**. Postinfantile giant cell hepatitis with features of acute severe autoimmune hepatitis probably triggered by diclofenac in a patient with primary myelofibrosis. *Case Rep Hepatol* 2018:9793868.
220. Wranke A, Pinheiro Borzacov LM, Parana R, Lobato C, Hamid S, Ceausu E, **Dalekos GN**, Rizzetto M, Turcanu A, Niro GA, Lubna F, Abbas M, Ingiliz P, Buti M, Ferenci P, Vanwolleghem T, Hayden T, Dashdorj N, Motoc A, Cornberg M, Abbas Z, Yurdaydin C, Manns MP, Wedemeyer H, Hardtke S; Hepatitis Delta International Network. Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN). *Liver Int* 38:842-850, 2018.
221. Murillo Perez F, Goet JC, Lammers WJ, Gulamhusein A, van Buuren HR, Ponsioen CY, Carbone M, Mason A, Corpechot C, Invernizzi P, Mayo MJ, Battezzati PM, Floreani A, Pares A, Nevens F, Kowdley KV, Bruns T, **Dalekos GN**, Thorburn D, Hirschfield G, LaRusso NF, Lindor KD, Zachou K, Poupon R, Trivedi PJ, Verhelst X, Janssen HLA, Hansen BE; GLOBAL PBC Study Group. Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. *Hepatology* 67:1920-1930, 2018.
222. Alberts R, de Vries EMG, Goode EC, Jiang X, Sampaziotis F, Rombouts K, Böttcher K, Folseraas T, Weismüller TJ, Mason AL, Wang W, Alexander G, Alvaro D, Bergquist A, Björkström NK, Beuers U, Björnsson E, Boberg KM, Bowlus CL, Bragazzi MC, Carbone M, Chazouillères O, Cheung A, **Dalekos G**, Eaton J, Eksteen B, Ellinghaus D, Färkkilä M, Festen EAM, Floreani A, Franceschet I, Gotthardt DN, Hirschfield GM, Hoek BV, Holm K, Hohenester S, Hov JR, Imhann F, Invernizzi P, Juran BD, Lenzen H, Lieb W, Liu JZ, Marschall HU, Marziani M, Melum E, Milkiewicz P, Müller T, Pares A, Rupp C, Rust C, Sandford RN, Schramm C, Schreiber S, Schrupf E, Silverberg MS, Srivastava B, Sterneck M, Teufel A, Vallier L, Verheij J, Vila AV, Vries B, Zachou K; International PSC Study Group, The UK PSC Consortium, Chapman RW, Manns MP, Pinzani M, Rushbrook SM, Lazaridis KN, Franke A, Anderson CA, Karlsen TH, Ponsioen CY, Weersma RK. Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. *Gut* 67:1517-1524, 2018.
223. Papatheodoridis GV, Sypsa V, **Dalekos G**, Yurdaydin C, Van Boemmel F, Buti M, Goulis J, Luis Calleja J, Chi H, Manolakopoulos S, Loglio A, Siakavellas S, Gatselis N, Keskin O, Lehretz M, Savvidou S, de la Revilla J, Hansen BE, Kourikou A, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HLA, Berg T, Lampertico P. 8-year survival in

chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. *J Hepatol* 68:1129-1136, 2018.

224. Georgiadou SP, Manoulakas E, Makaritsis K, **Dalekos GN**. A chronic alcoholic man with high fever, neck rigidity and loss of consciousness: Remember the Austrian syndrome a commonly unrecognized invasive pneumococcus triad. *BMJ Case Reports pii: bcr-2018-225010*, 2018.
225. Sveroni D, Stefos A, Rigopoulou EI, **Dalekos GN**. Rifampicin: not always an innocent drug. *BMJ Case Reports pii: e227356*, 2018.
226. **Dalekos GN**, Lygoura V, Gatselis NK. Variants of primary biliary cholangitis: An updated mini review. *J Autoimmune Dis Rheumatol* 6:21-28, 2018. **(Invited review)**.
227. Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, Zachou K, Xourafas V, Gatselis N, Hadziyannis E, Vlachogiannakos J, Manolakopoulos S, **Dalekos GN**. DARING-B: Discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B. *Antivir Ther* 23:677-685, 2018.
228. **Dalekos GN**, Koskinas J, Papatheodoridis GV. Hellenic Association for the Study of the Liver (HASL) Clinical Practice Guidelines: Autoimmune Hepatitis. *Ann Gastroenterol* 32:1-23, 2019.
229. Malli E, Gatselis NK, **Dalekos GN**, Petinaki E. Combination of vial culture and broad-range PCR for the diagnosis of spontaneous bacterial peritonitis: experience in a Greek tertiary care hospital. *New Microbe and New Infect* 28:1-5, 2019.
230. Zachou K, Arvaniti P, Azariadis K, Lygoura V, Gatselis NK, Lyberopoulou A, Koukoulis GK, **Dalekos GN**. Prompt initiation of high-dose i.v. corticosteroids seems to prevent progression to liver failure in patients with original acute severe autoimmune hepatitis. *Hepatol Res* 49:96-104, 2019.
231. Dyson JK, De Martin E, **Dalekos GN**, Drenth JPH, Herkel J, Hubscher SG, Kelly D, Lenzi M, Milkiewicz P, Oo YH, Heneghan MA, Lohse AW, on behalf of the IAIHG Consortium. Review article: unanswered clinical and research questions in autoimmune hepatitis- conclusions of the International Autoimmune Hepatitis Group Research Workshop. *Aliment Pharmacol Ther* 49:528-536, 2019.
232. Zachos I, Zachou K, **Dalekos GN**, Tzortzis V. Management of patients with liver cirrhosis and invasive bladder cancer: A case-series. *J Trans Int Med* 7:29-33, 2019.
233. Azariadis K, Gatselis NK, Koukoulis GK, **Dalekos GN**. Glycogenic hepatopathy as a cause of severe deranged liver enzymes in a young patient with type 1 diabetes mellitus. *BMJ Case Rep pii: e228524*, 2019.
234. Yurdaydin C, Abbas Z, Buti M, Cornberg M, Esteban R, Etzion O, Gane EJ, Gish RG, Glenn JS, Hamid S, Heller T, Koh C, Lampertico P, Lurie Y, Manns M, Parana R, Rizzetto M, Urban S, Wedemeyer H; **Hepatitis Delta International Network (HDIN)**. Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. *J Hepatol* 70:1008-1015, 2019.
235. Rigopoulou EI, Gyftaki S, Arvaniti P, Tsimourtou V, Koukoulis GK, Hadjigeorgiou G, **Dalekos GN**. Autoimmune hepatitis in patients with multiple sclerosis: The role of immunomodulatory treatment. *Clin Res Hepatol Gastroenterol* 43:e25-e32, 2019.
236. Papatheodoridis GV, Goulis J, Sypsa V, Lionis C, Manolakopoulos S, Elefsiniotis I, Anagnostou O, Tsoulas C, Hatzakis A, **Dalekos GN**. Aiming towards hepatitis C virus elimination in Greece. *Ann Gastroenterol* 32:321-329, 2019.
237. **Dalekos GN**, Gatselis NK. Variant and specific forms of autoimmune cholestatic liver diseases: A short review. *Arch Immunol Ther Exp (Warsz)* 67:197-211, 2019. **(Invited review)**.

238. Arvaniti P, Zachou K, Lyberopoulou A, Gatselis NK, Brooks WH, **Dalekos GN**, Renaudineau Y. Epigenetic modifications in generalized autoimmune epithelitis: Sjögren's syndrome and primary biliary cholangitis. *Epigenoms* 3,15, 2019.
239. Cheung AC, Lammers WJ, Murillo Perez CF, van Buuren HR, Gulamhusein A, Trivedi PJ, Lazaridis KN, Ponsioen CY, Floreani A, Hirschfield GM, Corpechot C, Mayo MJ, Invernizzi P, Battezzati PM, Parés A, Nevens F, Thorburn D, Mason AL, Carbone M, Kowdley KV, Bruns T, **Dalekos GN**, Gatselis NK, Verhelst X, Lindor KD, Lleo A, Poupon R, Janssen HL, Hansen BE. Effects of age and sex of on response to ursodeoxycholic acid and transplant-free survival in patients with primary biliary cholangitis. *Clin Gastroenterol Hepatol* 17:2076-2084, 2019.
240. **Dalekos GN**, Gatselis NK, Zachou K. Acute severe autoimmune hepatitis: corticosteroids or liver transplantation? The importance of the absence of any sign of encephalopathy. *Liver Transpl* 25:1588-1589, 2019.
241. Murillo Perez CF, Hirschfield GM, Corpechot C, Floreani A, Mayo MJ, van der Meer A, Ponsioen CY, Lammers WJ, Parés A, Invernizzi P, Carbone M, Maria Battezzati P, Nevens F, Kowdley KV, Thorburn D, Mason AL, Trivedi PJ, Lindor KD, Bruns T, **Dalekos GN**, Gatselis NK, Verhelst X, Janssen HLA, Hansen BE, Gulamhusein A. Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. *Aliment Pharmacol Ther* 50:1127-36, 2019.
242. Georgiadou S, Gatselis NK, Stefos A, Zachou K, Makaritsis K, Rigopoulou EI, **Dalekos GN**. Efficient management of secondary haemophagocytic lymphohistiocytosis with intravenous steroids and γ -immunoglobulin infusions. *World J Clin Cases* 7:3394-406, 2019.
243. Charras A, Arvaniti P, Le Dantec C, **Dalekos GN**, Zachou K, Bordron A, Renaudineau Y. JAK inhibitors and oxidative stress control. *Front Immunol* 10:2814, 2019.
244. Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D, Vierling JM, Adams D, Alpini G, Banales JM, Beuers U, Björnsson E, Bowlus C, Carbone M, Chazouillères O, **Dalekos G**, De Gottardi A, Harada K, Hirschfield G, Invernizzi P, Jones D, Krawitt E, Lanzavecchia A, Lian ZX, Ma X, Manns M, Mavilio D, Quigley EM, Sallusto F, Shimoda S, Strazzabosco M, Swain M, Tanaka A, Trauner M, Tsuneyama K, Zigmond E, Gershwin ME. The challenges of primary biliary cholangitis: What is new and what needs to be done. *J Autoimmun* 105:102328, 2019.
245. Bakarozzi M, Mavropoulos A, Bogdanos DP, **Dalekos GN**, Rigopoulou EI. p38 mitogen-activated protein kinase impairment of innate immune cells is a characteristic feature of HBeAg-negative chronic hepatitis B. *J Viral Hepat* 27:52-60, 2020.
246. Papatheodoridi M, Hadziyannis E, Berby F, Zachou K, Testoni B, Rigopoulou E, Gatselis NK, Lyberopoulou A, Vlachogiannakos I, Manolakopoulos S, **Dalekos GN**, Zoulim F, Papatheodoridis GV. Predictors of HBsAg loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in non-cirrhotic HBeAg-negative chronic hepatitis B. *J Viral Hepat* 27:118-126, 2020.
247. Zachou K, Weiler-Normann C, Muratori L, Muratori P, Lohse AW, **Dalekos GN**. Permanent immunosuppression in SLA/LP-positive autoimmune hepatitis is required although overall response and survival are similar. *Liver Int* 40:368-376, 2020.
248. Gatselis NK, Goet JC, Zachou K, Lammers WJ, Janssen HLA, Hirschfield G, Corpechot C, Lindor KD, Invernizzi P, Mayo MJ, Battezzati PM, Floreani A, Pares A, Lygoura V, Nevens F, Mason AL, Kowdley KV, Ponsioen CY, Bruns T, Thorburn D, Verhelst X, Harms MH, van Buuren HR, Hansen BE, **Dalekos GN**. Factors associated with progression and outcome in early stage primary biliary cholangitis. *Clin Gastroenterol Hepatol* 18:684-692, 2020.

249. Charras A, Arvaniti P, Le Dantec Ch, **Dalekos GN**, Zachou K, Bordon A, Renaudineau Y. JAK inhibitors suppress innate epigenetic reprogramming: a promise for patients with Sjögren's syndrome. *Clin Rev Allerg Immunol* 58:182-93, 2020.
250. Hartl J, Miquel R, Zachou K, Wong G-W, Ashgar A, Pape S, Sebode M, Peiseler M, Zenouzi R, Ehlken H, Krech T, Weiler-Normann C, Drenth JPH, Oo HY, **Dalekos GN**, Heneghan M, Schramm C, Lohse AW. Features and outcome of AIH patients with normal IgG. *JHEP Rep* 2:100094, 2020.
251. Arvaniti P, Le Dantec C, Charras A, Arleevskaia MA, Hedrich CM, Zachou K, **Dalekos GN**, Renaudineau Y. Linking genetic variation with epigenetic profiles in Sjögren's syndrome. *Clin Immunol* 210:108314, 2020.
252. **Dalekos GN**, Gatselis NK, Zachou K, Koukoulis GK. NAFLD and autoimmune hepatitis: Do not judge a book by its cover. *Eur J Intern Med* 75:1-9, 2020. **(Invited review)**.
253. Papatheodoridis GV, Sypsa V, **Dalekos GN**, Yurdaydin C, Van Boemmel F, Buti M, Calleja CL, Chi H, Goulis J, Manolakopoulos S, Loglio A, Voulgaris T, Gatselis N, Keskin O, Veelken R, Lopez-Gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos J, Galanis K, Idilman R, Esteban R, Janssen HLA, Berg T, Lampertico P. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. *J Hepatol* 72:1088-96, 2020.
254. Murillo Perez CF, Harms MH, Lindor KD, van Buuren HR, Hirschfield GM, Corpechot C, van der Meer AJ, Feld JJ, Gulamhusein A, Lammers WJ, Ponsioen CY, Carbone M, Mason AL, Mayo MJ, Invernizzi P, Battezzati PM, Floreani A, Lleo A, Nevens F, Kowdley KV, Bruns T, **Dalekos GN**, Gatselis NK, Thorburn D, Trivedi PJ, Verhelst X, Parés A, Janssen HLA, Hansen BE. Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase. *Am J Gastroenterol* 115:1066-1074, 2020.
255. Deng Y, Campbell F, Han K, Theodore D, Deeg M, Huang M, Hamatake R, Lahiri S, Chen S, Horvath G, Manolakopoulos S, **Dalekos GN**, Papatheodoridis G, Goulis I, Banyai T, Jilma B, Leivers M. Randomized clinical trials towards a single-visit cure for chronic hepatitis C: Oral GSK2878175 and injectable RG-101 in chronic hepatitis C patients and long-acting injectable GSK2878175 in healthy participants. *J Viral Hepat* 27:699-708, 2020.
256. Arvaniti P, Giannoulis G, Gabeta S, Zachou K, Koukoulis GK, **Dalekos GN**. Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis. *JHEP Rep* 2:100123, 2020.
257. Tampaki M, Gatselis NK, Savvanis S, Koullias E, Saitis A, Gabeta S, Deutsch M, Manesis E, **Dalekos GN**, Koskinas J. Wilson disease: 30-year data on epidemiology, clinical presentation, treatment modalities and disease outcomes from 2 tertiary Greek centers. *Eur J Gastroenterol Hepatol* 32:1545-1552, 2020.
258. Wranke A, Hardtke S, Heidrich B, **Dalekos G**, Yalçın K, Tabak F, Gürel S, Çakaloğlu Y, Akarca US, Lammert F, Häussinger D, Müller T, Wöbse M, Manns MP, Idilman R, Cornberg M, Wedemeyer H, Yurdaydin C. Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta. *J Viral Hepat* 27:1359-1368, 2020.
259. Papatheodoridis GV, **Dalekos GN**, Idilman R, Sypsa V, Van Boemmel F, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Loglio A, Papatheodoridi M, Gatselis N, Veelken R, Lopez-Gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos J, Galanis K, Yurdaydin C, Esteban R, Janssen HLA, Berg T, Lampertico P. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. *J Hepatol* 73:1037-1045, 2020.

260. Gatselis NK, Tornai T, Shums Z, Zachou K, Saitis A, Gabeta S, Albesa R, Norman GL, Papp M, **Dalekos GN**. Golgi protein-73: A biomarker for assessing cirrhosis and prognosis of liver disease patients. *World J Gastroenterol* 26:5130-5135, 2020.
261. Fan R, Papatheodoridis G, Sun J, Innes H, Toyoda H, Xie Q, Mo S, Sypsa V, Guha IN, Kumada T, Niu J, **Dalekos G**, Yasuda S, Barnes E, Lian J, Suri V, Idilman R, Barclay ST, Dou X, Berg T, Hayes PC, Flaherty JF, Zhou Y, Zhang Z, Buti M, Hutchinson SJ, Guo Y, Calleja JL, Lin L, Zhao L, Chen Y, Janssen H, Zhu C, Shi L, Tang X, Gaggari A, Wei L, Jia J, Irving WL, Johnson PJ, Lampertico P, Hou J. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. *J Hepatol* 73:1368-1378, 2020.
262. Azariadis K, Giannoulis G, Gabeta S, Michail A, Zachou K, **Dalekos GN**. Severe pharyngodynia followed by migratory polyarthritides and high fever in young immigrants: remember that rheumatic fever is still relevant in 2020! *Case Rep Infect Dis* doi: 10.1155/2020/8854868 eCollection, 2020.
263. Bertsimas D, Lukin G, Mingardi L, Nohadani O, Orfanoudaki A, Stellato B, Wiberg H, Gonzalez-Garcia S, Parra-Calderón CL, Robinson K, Schneider M, Stein B, Estirado A, A Beccara L, Canino R, Dal Bello M, Pezzetti F, Pan A; **Hellenic COVID-19 Study Group**. COVID-19 mortality risk assessment: An international multi-center study. *PLoS One* 15:e0243262, 2020.
264. Vatidis G, Rigopoulou EI, Tepetes K, **Dalekos GN**. Hepatic brucellosis: a rare complication of a common zoonotic disease. *BMJ Case Rep* 13:e237076, 2020.
265. **Dalekos GN**, Gatselis NK, Koukoulis GK. Non-alcoholic steatohepatitis or autoimmune hepatitis? Sometimes a closer look under the surface is needed. *BMJ Case Reports* 13:e238400, 2020.
266. Siakavellas S, Goulis J, Manolakopoulos S, Triantos C, Gatselis N, Tsentemidou E, Kranidioti H, Zisimopoulos K, Tsoulas C, **Dalekos G**, Papatheodoridis G. Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogues. *Ann Gastroenterol* 34:73-79, 2021.
267. Galaski J, Weiler-Normann C, Schakat M, Zachou K, Muratori P, Lampalzer S, Haag F, Schramm C, Lenzi M, **Dalekos GN**, Lohse AW. Update of the simplified criteria for autoimmune hepatitis: evaluation of the methodology for immunoserological testing. *J Hepatol* 74:312-320, 2021.
268. Gerussi A, Bernasconi DP, O'Donnell SE, Lammers WJ, Buuren HV, Hirschfield G, Janssen H, Corpechot C, Reig A, Pares A, Battezzati PM, Zuin MG, Cazzagon N, Floreani A, Nevens F, Gatselis N, **Dalekos G**, Mayo MJ, Thorburn D, Bruns T, Mason AL, Verhelst X, Kowdley K, van der Meer A, Niro GA, Beretta-Piccoli BT, Marziani M, Belli LS, Marra F, Valsecchi MG, Lindor KD, Invernizzi P, Hansen BE, Carbone M. Measurement of gamma glutamyl transferase to determine risk of liver transplantation or death in patients with primary biliary cholangitis. *Clin Gastroenterol Hepatol* 2021 (in press).
269. Kausik K Ray, Bart Molemans, W Marieke Schoonen, Periklis Givonas, Sarah Bray, Gaia Kiru, Jennifer Murphy, Maciej Banach, Stefano De Servi, Dan Gaita, Ioanna Gouni-Berthold, G Kees Hovingh, Jacek J Jozwiak, J Wouter Jukema, Robert Gabor Kiss, Serge Kownator, Helle K Iversen, Vincent Maher, Luis Masana, Alexander Parkhomenko, André Peeters, Piers Clifford, Katarina Raslova, Peter Siostrzonek, Stefano Romeo, Dimitrios Tousoulis, Charalambos Vlachopoulos, Michal Vrablik, Alberico L Catapano, Neil R Poulter, Robert Kiss, Vincent MG Maher, Johan W Jukema, Jacek Jozwiak, Luis Masana, Oleksander Parkhomenko, Klaus Distelmaier, Thomas M Stulnig, Heinz Drexel, Christoph Ebenbichler, Robert Zweiker, Helmut Brath, Gudrun Zweiker, Luc Janssens, Philippe van de Borne, Attilio Leone, Robin Lemmens, Ann A Verhaegen, Marc De Meulemeester, Yohan Balthazar, Stéphane Heijmans,

Yvan Calozet, Nicolas Paquot, Stéphane G Carlier, Dimitri Hemelsoet, Tomáš Velimský, Pavel Kolečkář, Ivana Kellnerová, Vladimír Cech, Jan Machač, Norbert Kral, Bohumil Seifert, Janka Škrobáková, Jiří Krupička, Jes S Lindholt, Christina Kruuse, Emmanuel Touzé, Joel Constans, JF Renucci, Philippe G Steg, Nabil Chakfe, Michel Farnier, Franck Bocarra, Grit Faulmann, Frank Schaper, Burkhard Manfras, Andreas Schäfer, Norbert Weiss, Frank Dellanna, Ulrike Schatz, Moses Elisaf, **George N Dalekos**, Daniel Bereczki, Katalin Farkas, Martyin Tibor, Laszlo Fehér, Verica Kiss, Robert G Kiss, Laszlo Mark, Peter Harrington, Brendan McAdam, Brian PO O'Doherty, Patricia M O'Connor, David Molony, Maurizio Aversa, Roberto Cemin, Fabio Verzini, Giuseppe Derosa, Salvatore Novo, Francesco Giorgino, Frank-Erik de Leeuw, Gerard K Hovingh, Pim van der Harst, Frank LJ Visseren, Jacek J Józwiak, Grzegorz Gajos, Monika Lukaszewicz, Jaroslaw D Kasprzak, Sławomir Kasperczyk, Jaroslaw Krawczyk, Anca Cerghizan, Noemi Pletea, Mircea I Popescu, Ionut Donoiu, Ion Ionescu, Boris Raska, Peter Bojčik, Jaime Masjuán-Vallejo, Esteban Jodar, Francisco Gomez-Delgado, Francisco J Tinahones, Alfonso Soto González, Jaime Garcia de Tena, Carlos Brotons, Anders Gottsäter, Ann Charlotte Laska, Åke Olsson, Carl-Johan Lindholm, Niclas Abrahamsson, Paul Ainsworth, Colin Bicknell, Ian C Chetter, Patrick Eavis, Paul Guylar, Timothy Hall, Robert J Hinchliffe, Peter Holt, Wayne M Turner, David Weston, David MacFarlane, Keith W Muir, David Julian A Scott, Matt Bown, Oleksandr Karpenko, Igor P Vakaliuk, Iurii Rudyk, Oleksii Korzh, Larysa M Yena, Kopytsya Mykola Pavlovych, Halyna Myshanych. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. *Eur J Prev Cardiol* 2021 (in press).

270. Derben FC, Engel B, Zachou K, Hartl J, Hartleben B, Bantel H, Schramm C, **Dalekos GN**, Manns MP, Jaeckel E, Taubert R. CK-18 cell death markers improve the prediction of histological remission in autoimmune hepatitis during biochemical remission. *Liver Int* 41:123–127, 2021.
271. Zachou K, Lygoura V, Arvaniti P, Giannoulis G, Gatselis NK, Koukoulis GK, **Dalekos GN**. FibroMeter scores for the assessment of liver fibrosis in patients with autoimmune liver diseases. *Ann Hepatol* 2021 (in press).
272. Sonneveld MJ, Park JY, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bömmel F, Berg T, Zoulim F, Ahn SH, **Dalekos GN**, Erler NS, Höner Zu Siederdisen C, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Maasoumy B; CREATE study group. Prediction of sustained response after nucleos(t)ide analogue cessation using hbsag and hbcrag levels - a multicenter study (CREATE). *Clin Gastroenterol Hepatol* 2021 (in press).
273. Murillo Perez CF, Gulamhusein A, Carbone M, Trivedi PJ, van der Meer AJ, Corpechot C, Battezzati PM, Lammers WJ, Cazzagon N, Floreani A, Parés A, Nevens F, Lleo A, Mayo MJ, Kowdley KV, Ponsioen CY, **Dalekos GN**, Gatselis NK, Thorburn D, Mason AL, Janssen H, Verhelst X, Bruns T, Lindor KD, Chazouillères O, Invernizzi P, Hansen BE, Hirschfield GM. Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis study group age, bilirubin, alkaline phosphatase risk assessment tool. *Eur J Gastroenterol Hepatol* 2021 (in press).
274. Thair SA, He YD, Hasin-Brumshtein Y, Sakaram S, Pandya R, Toh J, Rawling D, Remmel D, Coyle S, **Dalekos GN**, Koutsodimitropoulos I, Vlachogianni G, Gkeka E, Karakike E, Damoraki G, Antonakos N, Khatri P, Giamarellos-Bourboulis EJ, Sweeney TE. Transcriptomic similarities and differences in host response between SARS-CoV-2 and other viral infections. *iScience* 24:101947, 2021.
275. Papamichalis PA, Zachou K, Papamichali RA, Ioannou M, Gatselis NK, **Dalekos GN**, Koukoulis GK. Promyelocytic leukaemia (PML) antigen expression: a histological marker for primary biliary cholangitis diagnosis? *J Transl Int Med* 2021 (in press).

276. Rigopoulou EI, Gatselis NK, Arvaniti P, Koukoulis GK, **Dalekos GN**. Alcoholic liver disease and autoimmune hepatitis: Sometimes a closer look under the surface is needed. *Eur J Intern Med* 2021 (in press).
277. Rigopoulou EI, Gatselis NK, Galanis K, Lygoura V, Gabeta S, Zachou K, **Dalekos GN**. The changing epidemiology of hepatitis B in Greece. *Ann Gastroenterol* 2021 (in press).

C. Chapters in Books and/or electronic publications

1. **G.N. Dalekos**. *Infections of Hepatotropic Viruses in Multitransfused Patients-Therapeutic approaches*. Syllabuses of the Meeting (Sickle Cell Disease and Thalassaemia), University of Ioannina, Medical School, Child Health Department, Ioannina, Greece, October 8-9, 1994, S-15.
2. E.V. Tsianos, **G.N. Dalekos**. *Primary Sclerosing Cholangitis*. In: Postgraduate Courses in Gastroenterology. University Studio Press, Thessaloniki, Greece, 1996, p. 203-212.
3. **G.N. Dalekos**, E.V. Tsianos. *Aetiopathogenesis of Inflammatory Bowel Disease*. In: Proceedings of the XVI Panhellenic Congress in Gastroenterology. Athens, Greece, 1996, p. 65-83.
4. E.V. Tsianos, **G.N. Dalekos**. *The Liver in Autoimmune Rheumatic Diseases*. In: Postgraduate Courses in Hepatology, Volume IV, Athens, Greece, 1996, p. 71-89.
5. **G.N. Dalekos**. *Immunologic Mechanisms in Inflammatory Bowel Disease*. In: Proceedings of the IIIrd Panhellenic Symposium on Inflammatory Bowel Disease. University Studio Press, Thessaloniki, Greece, 1997, p. 34-53.
6. E.V. Tsianos, **G.N. Dalekos**. *The Gastrointestinal Tract and the Liver in Pregnancy*. In: Textbook of Gynecology and Obstetrics by D. Lolis (Ed), G.Parisianos, Athens, Greece, 1998, p. 519-536.
7. **G.N. Dalekos**. *Laboratory Evaluation in the Diagnosis and Differential Diagnosis of Primary Biliary Cirrhosis and Autoimmune Hepatitis*. In: Proceedings of the 6th Panhellenic Congress of the Hellenic Association for the Study of the Liver, Thessaloniki, Greece, 1999, p. 124-135.
8. **G.N. Dalekos**. *Nucleoside Analogues in the Treatment of Chronic HBeAg (+) Hepatitis B*. In: Proceedings of the 25th Panhellenic Congress of Medicine, Athens, Greece, 1999, p. 57-65.
9. **G.N. Dalekos**. *Famciclovir for the Treatment of Chronic Hepatitis B*. In: Proceedings of the 1st Symposium in Hepatitis B, Athens, Greece, 2000, p. 122-128.
10. P. Obermayer-Straub, J. Perheentupa, S. Braun, A. Kayser, A. Barut, S. Loges, A. Harms, **G. Dalekos**, C.P. Strassburg, M.P. Manns. *Hepatic Autoantigens in Patients with Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy*. In: Autoantigens and Autoantibodies: Diagnostic Tools and Clues to Understanding Autoimmunity, Conrad K, Humbel R-L, Meurer M, Shoenfeld, Tan EM (Eds.), Pabst Science Publishers, 2000.
11. **G.N. Dalekos**, E. Makri. *Epidemiological, Clinical and Laboratory Characteristics – Diagnostic Criteria of Autoimmune Hepatitis*. In: Proceedings of the Postgraduate Course in Hepatology, Athens, Greece, 2000, p. 68-82.
12. **G.N. Dalekos**. *Current Aspects in Autoimmune Hepatitis*. In: Proceedings of the 7th Panhellenic Congress of the Hellenic Association for the Study of the Liver, Athens, Greece, 2001, p. 78-92.
13. **G.N. Dalekos**. *Portal Hypertension: Pathophysiology and Pathogenesis*. In: Postgraduate Courses in Gastroenterology, University Studio Press, Thessaloniki, Greece, 2001, p. 46-55.

14. **G.N. Dalekos**, C. Liaskos, K. Zachou, E. Makri, M. Venizelos. *Management of asymptomatic patients with elevated liver function tests*. Hellenic Center for the Control of Infectious Diseases (Ed), Hellenic Ministry of Health, 2001.
15. **G.N. Dalekos**. *Autoimmune hepatitis: Pathogenesis, Diagnosis, clinical manifestations and treatment*. In: Postgraduate Courses in Pathology, Volcano press, Athens, 2001, p. 42-49.
16. **G.N. Dalekos**. *Cytokines in Inflammatory Bowel Disease*. In: *Inflammatory Bowel Disease: The Greek Experience*, edited by the Heraklion (Creta) Medical School, Heraklion, Greece, 2001, p.87-100.
17. **G.N. Dalekos**. *Liver and lung*. In: *Proceedings of the Postgraduate Course in Hepatology*, University Studio Press, Thessaloniki, Greece, 2001, p. 24-39.
18. **G.N. Dalekos**, G. Papadamou. *Treatment of chronic hepatitis C*. In: *Proceedings of the Postgraduate Course in Hepatology*, University Studio Press, Athens, 2002, p. 133-146.
19. **G.N. Dalekos**. *Autoantibodies in the diagnosis of the diseases of the gastrointestinal tract and the liver*. In: *Proceedings of the 28th Panhellenic Congress of Medicine*, Athens, Greece, 2002, p. 1-14.
20. **G.N. Dalekos**. *Cytokines in Medicine: From Bench to Bedside*. In: *Postgraduate Courses in Surgery*. Athens, Greece, 2002, p. 35-51.
21. **G.N. Dalekos**. *Decision Making in the Treatment of Difficult Cases of Chronic Hepatitis C Virus Infection*. In: *Proceedings of the 8th Symposium on Hepatitis C*, by S.I. Hatziyannis (Ed), P.C. Paschalidis, Athens, Greece, 2003, p. 365-382.
22. **G.N. Dalekos**. *Autoantibodies in diseases of the liver and the alimentary tract*. In: *Diagnostic Immunology* edited by A.E. Germeris, Larissa, Greece, 2002, p. 1-13.
23. **G.N. Dalekos**. *Hepatitis B and C in Greece: an update from the Hellenic Center for Disease Control and Prevention*. In: *Proceedings of the 9th Symposium on Hepatitis C*, by S.I. Hatziyannis (Ed), P.C. Paschalidis, Athens, Greece, 2004, p. 18-26.
24. **G.N. Dalekos**. *Contribution of molecular virology in diagnosis and treatment of viral hepatitis*. In: *Proceedings of the Symposium of the Hellenic Association for the Study of the Liver on Viral Hepatitis*, Nicosia, Cyprus, Syllabuses of the Meeting, May 7-8, 2004, p. 18-24.
25. **G.N. Dalekos**. *The utility of molecular virology in the clinical management of chronic hepatitis C*. In: *Proceedings of the 24th Panhellenic Congress of Gastroenterology*, November 6-9, 2004, p.23-27.
26. G. Kitis, E. Manesis, M. Deutsch, B. Papadimitropoulos, S. Savas, G. Germanidis, J. Goulis, and **G.N. Dalekos**. *Decision making in hepatitis C*. In: *Proceedings of the 9th Symposium on Hepatitis B and C*, by S.I. Hatziyannis (Ed), ALFAPAK Ltd, Athens, 2005, p. 129-138.
27. **G.N. Dalekos**. *Autoimmune hepatitis: Impact of symptoms and cirrhosis on the natural history and outcome of the disease*. In: *News in Rheumatology*, October/November/December 2005, p. 29-30.
28. **G.N. Dalekos**. *Autoimmune liver diseases: Differential diagnosis and treatment*. In: *Proceedings of the Educational Seminar of the Hellenic Association of Research and Education in Primary Care*, Plastira lake, Karditsa, 2005, p. 85-102.
29. **G.N. Dalekos**. *Autoimmune liver diseases*. In: *Proceedings of the 20th Postgraduate course of the Hellenic Association of Immunology*, Athens, October 13-15, 2005, p.13-27.
30. E.Petinaki and **G.N. Dalekos**. *Molecular methods as tools for the diagnosis of bacterial infections: useful or useless?* In: R.M. Mohan (Ed). *Research Advances in Microbiology*, Global Research Network, 2006, p. 23-31.

31. **G.N. Dalekos.** «*Hereditary and Metabolic Diseases of the Liver*». Chapter 154, Cecil, Internal Medicine, 18th Greek edition, Mendor Editions, Athens, 2010, p. 1122-1128.
32. **G.N. Dalekos.** «*Bacterial, Parasitic, Fungal and Granulomatous Diseases of the Liver*». Chapter 155, Cecil, Internal Medicine, 18th Greek edition, Mendor Editions, Athens, 2010, p. 1128-1135.
33. **G.N. Dalekos.** «*Alcoholic and non-Alcoholic Steatohepatitis*». Chapter 156, Cecil, Internal Medicine, 18th Greek edition, Mendor Editions, Athens, 2010, p. 1135-1139.
34. **G.N. Dalekos.** «*Diseases of the Gall Bladder and Biliary Tract*». Chapter 159, Cecil, Internal Medicine, 18th Greek edition, Mendor Editions, Athens, 2010, p. 1152-1161.
35. E. Petinaki and **G.N. Dalekos.** *Cardiobacterium*. In: Dongyou Liu (Ed). Molecular detection of human bacterial pathogens, Taylor & Francis CRC Press, Chapter 70, 2011, p.811-814.
36. **G.N. Dalekos.** *Autoimmune hepatitis: Clinical and laboratory aspects*. In: Hellenic Association for the Study of Liver (Ed). Clinical Hepatology, University Studio Press, Thessaloniki, 2011, p. 303-314.
37. **G.N. Dalekos.** *Liver and autoimmunity*. In: Proceedings of the 22th Year of Internal Medicine Days, Third Department of Internal Medicine of the Medical School of the University of Athens, Athens, April 5-6, 2013, chapter of invited speakers on CD (7 pages).
38. G. Papatheodoridis, G. Germanidis, **G.N. Dalekos.** *Clinical Practice Guidelines for the Management of Hepatitis B Virus Infection*. Special edition by the Hellenic Center for Disease Control and Prevention, Hellenic Ministry of Health, Athens, 2013 (*online edition, www.keelpno.gr*).
39. G. Papatheodoridis, G. Germanidis, **G.N. Dalekos.** *Clinical Practice Guidelines for the Management of Hepatitis C Virus Infection*. Special edition by the Hellenic Center for Disease Control and Prevention, Hellenic Ministry of Health, Athens, 2013 (*online edition, www.keelpno.gr*).
40. **G.N. Dalekos.** *Autoimmune hepatitis and primary biliary cirrhosis: Models of clinical and laboratory challenges for the discovery of amazing diseases*. In: GM Chatzigeorgiou and Medical Editions Konstantaras (Eds). Honorary Volume to Prof. A. Papadimitriou, Athens, Chapter 32, 2013, p. 181-187.
41. G. Papatheodoridis, G. Germanidis, **G.N. Dalekos.** *Updated Clinical Practice Guidelines for the Management of Hepatitis C Virus Infection*. Special edition by the Hellenic Center for Disease Control and Prevention, Hellenic Ministry of Health, Athens, November 2014 (*online edition, www.keelpno.gr*).
42. **G.N. Dalekos,** K. Zachou, N.K. Gatselis, G.K. Koukoulis, J. Koskinas. *Clinical Practice Guidelines of the Hellenic Association for the Study of the Liver (HASL) on the Diagnosis and Management of Autoimmune Hepatitis*. HASL (ed.), Athens, April 2015 (*online edition, www.eemh.gr*).
43. J. Vlachogiannakos, G.V. Papatheodoridis, **G.N. Dalekos,** A. Alexopoulou, Ch. Triantos, E. Chologitas, J. Koskinas. *Clinical Practice Guidelines of the Hellenic Association for the Study of the Liver (HASL) for the Prevention and Treatment of HBV Reactivation during or after Immunosuppressive Therapy*. HASL (ed.), Athens, June 2015 (*online edition, www.eemh.gr*).
44. G. Papatheodoridis, G. Germanidis, **G.N. Dalekos.** *First revision on Clinical Practice Guidelines for the Management of Hepatitis C Virus Infection*. Special edition by the Hellenic

Center for Disease Control and Prevention, Hellenic Ministry of Health, Athens, December 2015 (*online edition, www.keelpno.gr*).

45. G. Papatheodoridis, G. Germanidis, **G.N. Dalekos**. *Second revision on Clinical Practice Guidelines for the Management of Hepatitis C Virus Infection*. Special edition by the Hellenic Center for Disease Control and Prevention, Hellenic Ministry of Health, Athens, April 2016 (*online edition, www.keelpno.gr*).
46. G. Papatheodoridis, G. Germanidis, **G.N. Dalekos**. *Clinical Practice Guidelines of the Hellenic Association for the Study of the Liver (HASL) on the Use of New Antivirals in Chronic Viral Hepatitis C*. HASL (ed.), Athens, January 2017 (*online edition, www.eemh.gr*).
47. G. Papatheodoridis, G. Germanidis, **G.N. Dalekos**. *Third revision on Clinical Practice Guidelines for the Management of Hepatitis C Virus Infection*. Special edition by the Hellenic Center for Disease Control and Prevention, Hellenic Ministry of Health, Athens, February 2017 (*online edition, www.keelpno.gr*).
48. **G.N. Dalekos**, E.I. Rigopoulou. «*Gastrointestinal, Liver and Biliary Tract System*». Chapter 9, Chamberlain's Clinical Examination and Diagnosis, Greek Edition, P.C. Paschalidis Editions, Athens, 2017, p. 166-205).
49. **G.N. Dalekos**, E.I. Rigopoulou. «*Cirrhosis of the Liver and its Complications*» (Chapter 43, Greek Edition Andreoli & Carpenter's Cecil Essentials of Medicine, P.C. Paschalidis Editions, Athens, 2017, p. 427-436).
50. **G.N. Dalekos**, E.I. Rigopoulou. «*Diseases of the gallbladder and the biliary tree*» (Chapter 44, Greek Edition Andreoli & Carpenter's Cecil Essentials of Medicine, P.C. Paschalidis Editions, Athens, 2017, p. 437-442).
51. **G.N. Dalekos**, K. Makaritsis. «*Vascular diseases of the brain*» (Chapter 116, Greek Edition Andreoli & Carpenter's Cecil Essentials of Medicine, P.C. Paschalidis Editions, Athens, 2017, p. 941-952).
52. **G.N. Dalekos**, K. Makaritsis. «*Traumatic injury of brain and spinal cord*» (Chapter 117, Greek Edition Andreoli & Carpenter's Cecil Essentials of Medicine, P.C. Paschalidis Editions, Athens, 2017, p. 953-957).
53. **G.N. Dalekos**, I. Goulis, S. Manolakopoulos, V. Papaevangelou, G. Papatheodoridis. *Clinical Practice Guidelines for the Management of Hepatitis B Virus Infection*. Special edition by the Hellenic Center for Disease Control and Prevention, Hellenic Ministry of Health, Athens, December 2017 (*online edition, www.keelpno.gr*).
54. G. Papatheodoridis, G. Germanidis, **G.N. Dalekos**. *Forth revision on Clinical Practice Guidelines for the Management of Hepatitis C Virus Infection*. Special edition by the Hellenic Center for Disease Control and Prevention, Hellenic Ministry of Health, Athens, February 2019 (*online edition, www.keelpno.gr*).
55. **G.N. Dalekos**. *Autoimmune hepatitis*. In: Hellenic Association for the Study of Liver (Ed). *Clinical Hepatology*, Focus on Health Ltd, Athens, 2019, p. 465-477.
56. **G.N. Dalekos** and N.K. Gatselis. Primary sclerosing cholangitis – Autoimmune hepatitis overlap. In: M. Eric Gershwin, John M. Vierling, Atsushi Tanaka, and Michael P. Manns (Eds). *Liver Immunology: Principles and Practice*, Springer International Publishing, Cham, Chapter 23, pp. 359-373, 2020.

D. Papers in Greek Medical Journals

1. **G.N. Dalekos**, P. Aggelis, K. Papadopoulos, D. Perakis. Fatal acute renal failure due to acute rhabdomyolysis in an heroin addict. *Psychiatry Letters* 24: 108-111, 1988.
2. **G.N. Dalekos**, K. Papadopoulos. Heatstroke: Current aspects of its pathophysiology, complications, treatment and prevention. *Iatriki* 56: 426-436, 1989.
3. **G.N. Dalekos**, P. Aggelis, D. Christodoulou, K. Katsikis. Dermatomyositis as first manifestation of pancreatic cancer. *Iatriki* 57: 74-77, 1990.
4. **G.N. Dalekos**, D. Kairis, E. Drimilis. Concentrations of magnesium in the sera of patients with delirium tremens due to alcohol withdrawal. *Psychiatry Letters* 33: 144-148, 1991.
5. **G.N. Dalekos**. Prostaglandins: Their role in cytoprotection and in cirrhosis of the liver. *Iatriki* 60: 231-242, 1991.
6. **G.N. Dalekos**, D. Kairis, P. Aggelis, K. Papadopoulos. Concentrations of selenium in the sera of patients with delirium tremens due to alcohol withdrawal. *Arch Hell Med* 8: 120-123, 1991.
7. **G.N. Dalekos**, C.N. Masalas, M. Merkouropoulos, E.V. Tsianos. Epidemiology of ulcerative colitis in the area of Epirus, Greece. *Hell J Gastroenterol* 4: 283-288, 1991.
8. K. Masalas, **G.N. Dalekos**, M. Merkouropoulos, E.V. Tsianos. The constipation as a presenting symptom at the first attack of ulcerative colitis. *Arch Hell Med* 9: 201-204, 1992.
9. **G.N. Dalekos**, M. Merkouropoulos, A. Mavridis, E. Zervou, K. Masalas, E.V. Tsianos. Frequency of hepatitis C in heroin addicts. *Iatriki* 63: 51-54, 1993.
10. **G.N. Dalekos**, E.V. Tsianos. Hepato-pulmonary syndrome: Is this a functional lung failure in liver cirrhosis? *Iatriki* 63: 449-458, 1993.
11. **G.N. Dalekos**, M. Stamouli, P. Aggelis. The glycosylated haemoglobin A₁ (HbA₁) in chronic heroin addicts during the withdrawal stage. *Psychiatry Letters* 42: 140-142, 1993.
12. **G.N. Dalekos**, M.N. Manoussakis, M.C. Merkouropoulos, E.V. Tsianos. Autoimmunity and cellular immune activation before and after α -interferon administration in Greek patients with chronic viral hepatitis. A preliminary study. *Hell J Gastroenterol* 6: 166-171, 1993.
13. **G.N. Dalekos**, M. Stamouli, E. Drimilis, G. Solias. Heroin as a cause of high mean cell volume. *Iatriki* 64: 637-640, 1993.
14. **G.N. Dalekos**, G.C. Liapi, P. Dallas, D. Stefanou, M. Elisaf. Hepatic dysfunction as first manifestation of renal cell carcinoma. A case report and review of the literature. *Hell J Gastroenterol* 6: 267-271, 1993.
15. L. Christou, **G.N. Dalekos**, E.V. Tsianos, K. Bourantas. Brucellosis and ascites. *Iatriki* 67: 77-79, 1995.
16. **G.N. Dalekos**, D.I. Anastasopoulos, M.H. Merkouropoulos, E.V. Tsianos. Choreic movements as neurologic manifestation of ulcerative colitis. Reality or coincidence? *Hell J Gastroenterol* 8: 75-77, 1995.
17. **G.N. Dalekos**, M. Elisaf, E. Bairaktari, N. Papagalanis, K.C. Siamopoulos. Interleukin-1 β in the systemic circulation of patients with familial hypercholesterolemia and essential hypertension: Additional risk factor for atherogenesis in hypertensive patients? *Arterial Hypertension* 4: 53-62, 1995.
18. **G.N. Dalekos**, E. Zervou, F. Karabini, H. Liapis, K. Ziciadis, E.V. Tsianos. Frequency of chronic hepatitis C virus (HCV) infection among individuals with indeterminate results after RIBA-II HCV test: A prospective study. Proceedings of the Second Symposium on Hepatitis C, by S.I. Hadziyannis (Ed), Athens, P. Paschalides (Pub.), 1995, p. 175-179.

19. **G.N. Dalekos**, E. Zervou, E.V. Tsianos. IgM antibodies to HCV in chronic active hepatitis C in north-western Greece. Solution or more questions? Proceedings of the Second Symposium on Hepatitis C, by S.I. Hadziyannis (Ed), Athens, P. Paschalides (Pub.), 1995, p. 180-183.
20. **G.N. Dalekos**, E.V. Tsianos. High concentrations of soluble interleukin-2 receptors and interleukin-6 in active ulcerative colitis. *Hell J Gastroenterol* 8: 319-327, 1995.
21. **G.N. Dalekos**, A. Vlachopoulos, E.V. Tsianos. The epidemiology of inflammatory bowel disease in Ioannina. *Iatriki* 69: 66-74, 1996.
22. **G.N. Dalekos**, E.V. Tsianos. Cytokines in inflammatory bowel disease. *Hell J Gastroenterol (Letter)*, 9: 75-76, 1996.
23. **G.N. Dalekos**, E. Zervou, E.V. Tsianos. Prevalence of anti-HCV antibodies in healthy individuals, chronic alcoholics and refugees from Albania in Epirus region-Greece Proceedings of the Third Symposium on Hepatitis C, by S.I. Hadziyannis (Ed), Athens, Paschalides, 1996, p. 157-163.
24. **G.N. Dalekos**, E. Zervou, D.S. Boumba, A. Gerolymatou, E.V. Tsianos. Frequency of viraemia due to hepatitis C virus (HCV) among individuals with indeterminate results after RIBA-II HCV test: A preliminary study. *Hell J Gastroenterol* 9: 160-166, 1996.
25. E. Ioachim, **G.N. Dalekos**, E.V. Tsianos, E. Demou, A.C. Goussia, N.J. Agnantis. Aberrant HLA-DR expression and lymphocyte subsets in inflammatory bowel disease: an immunohistological study on frozen and paraffin sections. *Hell J Gastroenterol* 9: 332-338, 1996.
26. E.V. Tsianos, **G.N. Dalekos**. Inflammatory bowel disease (I). Genetic factors and inflammatory mediators. *Iatriki* 71: 25-30, 1997.
27. **G.N. Dalekos**, E.V. Tsianos. Inflammatory bowel disease (II). Immunologic factors. *Iatriki* 71: 134-142, 1997.
28. **G.N. Dalekos**, M. Elisaf, E. Bairaktari, N. Papagalanis, O.Tsolas, K.C. Siamopoulos. Interleukin-1 β and essential hypertension. *Iatriki* 71: 573-580, 1997.
29. **G.N. Dalekos**, D. Boumba, E. Zervou, D. Christodoulou, K. Kistis, E.V. Tsianos. Equivalence (correlation) and clinical significance of serotypes and genotypes of hepatitis C virus: A preliminary study. Proceedings of the Fourth Symposium on Hepatitis C, by S.I. Hatziyannis (Ed), PRESS CONCEPT N. Heraklion, Athens, 1997, p. 183-188.
30. **G.N. Dalekos**, D. Christodoulou, K.G. Kistis, A. Gerolymatou, E.V. Tsianos. The role of interleukin-7 in the induction of the inflammatory cascade in ulcerative colitis patients. More questions than evidence. *Hell J Gastroenterol* 10: 51-53, 1997.
31. E. Zervou, **G.N. Dalekos**, D. Christodoulou, E.V. Tsianos. Prevalence of HCV serotype in Epirus by using an enzyme immunoassay. *Acta Microbiologica Hellenica* 42: 206-209, 1997.
32. E. Zervou, **G.N. Dalekos**, S. Alfantaki, E. Galanakis, P. Lapatsanis, E.V. Tsianos. Prevalence of anti-HAV IgG antibodies in pediatric population and blood donors in N.W. Greece. *Acta Microbiologica Hellenica* 42: 218-222, 1997.
33. **G.N. Dalekos**, E. Zervou, M. Elisaf, D.S. Boumba, K. Katopodis, G. Sferopoulos, K.C. Siamopoulos, E.V. Tsianos. Increased frequency of HGV-RNA detection in hemodialysis patients negative for other blood-borne viruses. *Hell J Gastroenterol* 10: 203-209, 1997.
34. E. Zervou, **G.N. Dalekos**, D. Christodoulou, A. Gerodemou, E.V. Tsianos. Correlation between anti-HBc positivity and HBV viraemia. *Iatriki*, 74: 400-403, 1998
35. E. Zervou, **G.N. Dalekos**, A. Gerolymatou, D. Boumba, E.V. Tsianos. Prevalence of hepatitis B and C markers in blood donors in Epirus. *Acta Microbiologica Hellenica* 43: 482-489, 1998

36. **G.N Dalekos**. Molecularly defined target-autoantigens as tools for the diagnosis, differential diagnosis and the study of aetiopathogenesis of autoimmune liver diseases. *Iatriki* 75: 408-418, 1999.
37. Ch. Liaskos, **G.N. Dalekos**. New concepts on the epidemiology and the clinical and laboratory markers for the diagnosis and differential diagnosis of autoimmune hepatitis. *Iatriki* 78: 233-243, 2000.
38. E.Zervou, P. Georgitsi, M. Tzoufi, G.N. Dalekos, M. Pontikaki, K. Zisiadis, E.V. tsianos. Prevalence and clinical characteristics of HGV infection in blood donors and patients with thalassemia major. *Acta Microbiologica Hellenica* 46: 167-171, 2001.
39. K. Zachou, Ch. Liaskos, E. Makri, G. Papadamou, M. Kardasi, A. Pliaka, F. gerovasilis, **G.N. Dalekos**. Anticardiolipin antibodies (a-CLAbs) are not b2-GPI-dependent (non-thrombogenic a-CLAbs): preliminary results in 107 HCV patients from central Greece. In: Proceedings of the 1st Symposium on Hepatitis B and C 2001-02, by S.I. Hatziyannis (Ed), Medical press P.C. Paschalidis, Athens, 2003, p. 392-402.
40. S. Georgiadou, K. Zachou, Ch. Liaskos, N. Gatselis, A. Tsikrikoni, F. Gerovasilis, M. Kardasi, E. Makri, G. Papadamou and **G.N. Dalekos**. Increased prevalence of occult hepatitis B virus infection in patients with chronic hepatitis C: absence of association with more severe liver disease. In: Proceedings of the 2nd Symposium on Hepatitis B and C 2003, by S.I. Hatziyannis (Ed), Medical press P.C. Paschalidis, Athens, 2004, σ. 304-315.
41. **G.N. Dalekos**. Autoantibodies and autoantigens associated with autoimmune hepatitis and viruses-induced autoimmune response: significant tools in clinical practice and in the study of pathogenesis of autoimmune hepatic diseases. *Archives of Hellenic Medicine* 21:502-527, 2004
42. E.I. Rigopoulou **and G.N. Dalekos**. Current treatment of HBV and HCV infections. *Drugs & Prescription* 11:16-24, 2005.
43. M. Speletas, F. Kalala, **G. Dalekos**. Continuing medical education. Clinical Immunology quiz-Case 1. *Archives of Hellenic Medicine* 24:398, 2007.
44. **G. Dalekos**. Autoimmune liver diseases: Aetiopathogenesis and diagnosis. *Anosia* 8:59-65, 2012.
45. N. Gatselis, **G.N. Dalekos**. Autoimmune hepatitis, one disease with many faces: Part I. *Hell J Med* 101:4-30, 2014.
46. K. Zachou, **G.N. Dalekos**. Autoimmune hepatitis, one disease with many faces: Part II. *Hell J Med* 102:58-73, 2014.
47. P. Arvaniti, Koukoulis GK, **Dalekos GN**, Zachou K. Postinfantile giant cell hepatitis with features of acute severe autoimmune hepatitis probably triggered by diclofenac in a patient with primary myelofibrosis. *Hell J Med* 120:238-245, 2018.

E. Citation Index (31-12-2020)

ISI and/or Scopus: **9236 citations** (self-citations: 136), **h-index = 46**

Google Scholar: **13696 citations**, **h-index = 57**, **i10-index = 192**

Total impact factor: **1720,055**

Note

1. I have also presented/participated 272 and 328 abstracts in Greek and International Congresses, respectively.
2. I have acted as faculty member, chairperson, moderator and/or speaker in several local (Greek) Congresses, International meetings like EASL, UEGW, AASLD, EFIM, IAIHG, European Society of Hypertension, European and Mediterranean League Against Thrombotic Diseases and International Immunology Congresses (n=478 in total).